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ABSTRACT
Parker, Ashley Cox. PhD. The University of Memphis. May 2014. Fungal and
Bacterial Infection Mitigation with Antibiotic and Antifungal Loaded Biopolymer
Sponges. Major Professor: Warren O. Haggard.
Musculoskeletal injuries are some of the most prevalent injuries in both civilian
and military populations and their infections can be difficult to treat, often resulting in
multiple surgeries and increased costs. In both previous and recent military operations,
extremity injuries have been the most common battlefield injuries and many involve
complex, open fractures. These extremity injuries are especially susceptible to multiple
pathogenic, and sometimes drug resistant, bacteria and fungi. Fungal infections have
recently become increasingly problematic in both military and civilian populations and
have significantly higher amputation rates than those from bacterial infections. Many of
these bacterial and fungal strains adhere to tissue and implanted orthopaedic hardware
within wounds, forming biofilms. These problematic, often polymicrobial, infections
threaten the health of the patient, but the risk also exists of spreading within hospitals to
become prominent resistant infections. Local antimicrobial delivery releases high levels
of antimicrobials directly to injured wound tissue, overcoming sub-bactericidal or subfungicidal antimicrobial levels present in the avascular wound zones. This research will
determine the ability of modified chitosan sponges, buffered with sodium acetate or
blended with polyethylene glycol (PEG), to act as short term adjunctive therapies to
initial surgical treatment for delivering both antibiotics and/or antifungals for early
abatement of infection. The objective of this work was to evaluate both types of
modified sponges for in vitro and in vivo material characteristics and device functionality.
In vitro analysis demonstrated both the buffered and PEG modified chitosan sponges
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exhibited increased degradation and functional cytocompatibility. The chitosan/PEG
sponges were able to be loaded with hydrophobic antifungals and the sponges released in
vitro biologically active concentrations, alone or in combination with the antibiotic
vancomycin. Both types of modified sponges exhibited good biocompatibility and slight,
but not complete, degradation in an in vivo rat intramuscular degradation and
biocompatibility model. In an in vivo bacteria biofilm infection prevention mouse model,
vancomycin loaded chitosan/PEG sponges also cleared more bacteria than the
unmodified chitosan sponges. These experimental results led to the conclusion that with
additional research and in vivo studies, the buffered and PEG blended chitosan sponge
local delivery systems exhibit potential for use as adjunctive bacterial or fungal infection
prevention therapies to standard surgical treatment of musculoskeletal wounds.
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CHAPTER 1
INTRODUCTION
Background
Musculoskeletal trauma, which is an injury to bone and/or muscle tissue, is one of
the most prevalent types of injuries in the United States. 1 More than three out of five of
the unintentional injuries occurring annually in the U.S. are musculoskeletal injuries.1 In
2004, approximately 57.2 million musculoskeletal injuries occurred in the U.S. and
20,000 of the injured patients died.1 The economic cost of these injuries is high due to
medical (hospitalization, post operative care, therapy, etc.) costs and salary loss; out of
the musculoskeletal injuries that occurred in 2004, 1.04 million people were hospitalized
for an average of 4.7 days, resulting in total estimated hospital costs of $26.65 billion and
$25,000 per patient.1
Infection associated with these musculoskeletal related injuries also has a
significant impact on patient morbidity and mortality and can be a devastating
complication.2 Infection and osteomyelitis, a bone infection caused by bacteria or a
fungus, are especially troublesome in open fractures, which are caused by high energy
trauma and typically result in both skeletal and soft tissue injury. The infection rates of
orthopaedic surgery (total hip arthroplasty) have been reported as 0.8-1.2% while the
reported infection rates of closed and open fractures are 3.6-8.1% and 17.5-21.2%,
respectively.3 Based on injuries through May 2003, the rate of infection was reported to
be 26.5% in soldiers with battlefield complex trauma. 4 During the Vietnam War,
infectious complications occurred in 3.9% of casualties and septic shock was determined
to be a leading cause of mortality.5
1

In the Iraq and Afghanistan wars (Operation Iraqi and Enduring Freedom),
extremity injuries were the most common combat injuries. These extremity injuries are
especially susceptible to multiple pathogenic, and sometimes drug resistant bacteria or
fungi, such as methicillin resistant Staphylococcus aureus (MRSA), Pseudomonas
aeruginosa, Acinetobacter baumannii, Escherichia coli, Aspergillus spp, or Candida
albicans (C. albicans).6,7 In addition to the presence of multidrug resistant bacteria or
fungi, the presence of necrotic tissue, debris, and fixation devices or implants creates a
favorable environment for the development of biofilms and corresponding infection. 8
According to an estimate by the CDC, approximately 65% of bacterial infections are
associated with biofilms.9 Biofilms are adherent (sessile) bacterial populations of single
or mixed colonies with protective mechanisms that enable them to communicate between
themselves and resist antibiotic and antimicrobial agents. 8,10 In biofilms, the metabolic
activity of the bacteria is reduced, resulting in less susceptibility to antimicrobials and an
increased minimal inhibitory concentration (MIC). 10 Researchers have found the MIC
for nonadherent P. aeruginosa to be 1 µg/ml tobramycin, but adherent P. aeruginosa in
biofilms on urinary catheters remained viable after 12 hours of exposure to tobramycin at
levels as high as 1,000 µg/ml.8,11 Systemic antibiotics cannot reach such a high
concentration at a localized site without toxicity, thereby becoming ineffective against the
biofilms.10
Invasive fungal infections have become recently troublesome for both military
and civilian populations, with high mortality rates and high healthcare costs. 2,12,13 The
British Military has recently reported higher rates of fungal wound infections in
casualties from the Helmand Province in Afghanistan.14 In a 2011 Trauma Infectious
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Disease Outcome Study (TIDOS), it was determined that 36 cases of invasive fungal
infections (IFI) were found in Operation Enduring Freedom soldiers with blast injuries in
Afghanistan from June 2009 to December 2010, and 78% of the wounded warriors with
IFI required lower extremity amputations. 15 An outbreak of cutaneous mucormycosis
was also recently reported in victims from the 2011 tornado in Joplin, Missouri. 16
Apophysomyces trapeziformis was identified in all 13 infected patients and 10 patients
required admission to intensive care, but 5 of the infected patients died.16,17 While
invasive fungal infections can be rare in patients without risk factors, higher incidences
have been found in transplant patients, African Americans, and babies younger than one
year old.18,19 Invasive Candida infection is the third most common cause of hospitalacquired bloodstream infections and is five times more prevalent in children than
invasive Aspergillus infection.19,20
Effective wound management often provides faster and more comfortable wound
healing, which increases patients’ quality of life. The common steps utilized in wound
management with orthopaedic injuries and surgical sites are debridement, irrigation,
dressings, fixation, closure, and systemic antibiotic therapy.21 All of these steps are
utilized by surgeons in order to prevent further damage to the tissues, amputation, or even
death. Because systemic antibiotics cannot be administered at very high concentrations
to fight localized bacteria, local antimicrobial delivery can be an effective route for
treating wounds and minimizing bacterial infections, when used as an adjunctive therapy
to systemic dosing.22 In addition to issues with antibiotic resistance, toxicity issues can
arise with systemic drug delivery because drugs are delivered to the entire body. 22 Local
antibiotic or antifungal delivery releases high levels of antibiotics directly to injured
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wound tissue, overcoming sub-bactericidal antibiotic levels present in the avascular
wound zones.22,10,23
Several materials are currently being utilized as local antibiotic delivery systems,
but many of these materials have disadvantages, including the need for a removal
surgery, the inability to load antibiotics directly in the operating room, and limited time
of delivery. Polymethylmethacrylate (PMMA) bone cement is one of the most common
materials used as a local antibiotic carrier for musculoskeletal infection prevention or
treatment.24 While bone cement has shown to reduce infection in severe open fractures,
some major disadvantages of the material are the need for surgical removal, possible
biofilm formation, and the development of antibiotic resistant bacteria. 10,25 Calcium
sulfate is another commonly used local antibiotic delivery material and is a
biocompatible, biodegradable material with osteoconductive properties. 26,27 Although
calcium sulfate exhibits an antibiotic bolus release followed by extended drug release
from several hours to weeks, wounds treated with calcium sulfate can develop sterile
draining sinuses that mimic infected draining sinuses and antibiotic choices and dosages
can be limited.26-29 The collagen sponge is also a degradable drug delivery system, but
despite the degradable nature and high local antibiotic release of these sponges, the high
initial level of antibiotics has been reported to generate toxic antibiotic serum levels and
potential immunogenic responses to the collagen sources can be another problem. 10,30
While antibiotics have been studied extensively in local delivery, antifungals have
not been successfully locally delivered from as many degradable delivery systems
because of their hydrophobicity for loading and distribution.

The hydrophobic

antifungal, amphotericin B, has also been incorporated into a few local delivery systems,

4

including poly(methyl methacrylate) bone cement, a hydroxyapatite and chitosan
composite, a Pluronic® based copolymer gel, and dextran hydrogels. 31-35 A drawback to
these developed local antifungal delivery systems is that most are pre-loaded with
antifungal and are not easily customized by the clinician. There is a clear need for a
degradable local delivery system alternative, such as a chitosan device, that can be loaded
with multiple antimicrobials, including antibiotics and antifungals, at the point of care to
provide clinicians with a viable adjunctive therapy to systemic antibiotic and antifungal
delivery.
Chitosan, a positively charged linear polysaccharide composed of β-(1-4)-2amino-2-D-glucosamine (deacetylated) and β-(1-4)-2-acetamido-2-D-glucosamine
(acetylated) units, has been studied extensively in bioadhesion, drug delivery and tissue
engineering research and demonstrates promising properties for such biomedical
applications.36-40 Chitosan is produced by deacetylation of the naturally occurring chitin
from crustacean shells, which is the second most abundant naturally occurring
polymer.40,41 Advantages of chitosan include low cost, biodegradability, high
biocompatibility, availability, and functional groups that allow for easy chemical
modification.42
Chitin and chitosan have different degrees of deacetylation (DDA); chitin
typically has DDA of less than 50% and chitosan has a DDA greater than 50%.

38

The

degree of deacetylation of chitosan affects degradation; as DDA increases, chitosan
becomes more resistant to degradation. 41 While in the human body, chitosan is degraded
by lysozyme, lipasases, chitosanases, and N-acetyl-o-glucosamindase.43 Lysozyme
degrades chitosan through cleavage of glycosidic bonds and has also shown to quickly
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degrade chitosan in vitro.44 Chitosan’s degradation products, glucosamines and
saccharides, do not elicit chronic foreign body reactions because the human body
gradually absorbs them.45
When used as a drug delivery system, chitosan effectively carries antibiotics and
exhibits biodegradation and predictable elution rates. 46 However, wide variations in in
vivo degradation of chitosan have been reported; Ma et al. found chitosan scaffolds to
exhibit minimal degradation after subcutaneous implantation, but Noel and researchers
reported rapid degradation of chitosan after use as a wound dressing.47,48 Previous
research conducted at the University of Memphis has yielded a topical, porous,
degradable chitosan sponge that provides an adaptable antibiotic delivery system in
which tailored dosing and degradation can be achieved.48,49 This system can be loaded
with antibiotics immediately prior to use, allowing for clinician selected antibiotic
loading, as well as combination loading.48,49 However, in order to load hydrophobic
antifungals into the chitosan sponges, the sponges must be modified, possibly with other
polymers that have previously shown antifungal solubility.
The water soluble polymer, polyethylene glycol (PEG) has been found to function
as a solvent system for a hydrophobic fatty acid, cis-2-decenoic acid, allowing for point
of care loading of the fatty acid into the chitosan sponges. 50 Polyethylene glycol exhibits
protein resistance, which is the resistance of protein accumulation on surfaces, low
toxicity and immunogenicity; when added to chitosan films, PEG also enhanced protein
adsorption, cell adhesion, growth, and proliferation. 51 In addition to films, PEG has been
used to modify chitosan fibers and hydrogels. 51-54 Modification of chitosan with PEG can
occur through blending, copolymerization, or by using PEG simply as the drug solvent.52-
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54

Polyethyelene glycol has also been utilized as a solvent system, either as liposomes or

nanoparticles, for amphotericin B in systemic delivery. 55-58
For the modified chitosan sponges investigated in this body of work, sodium
acetate buffered and PEG blended chitosan sponges were fabricated and evaluated for in
vitro material properties and functionality as degradable, biocompatible, local antibiotic
and/or antifungal delivery systems. The modified chitosan sponges were also investigated
in vivo to confirm biocompatibility, degradation, and infection prevention.
Hypothesis
Chitosan sponges, modified with either a buffer or polyethylene glycol (PEG) will
form a degradable local delivery system, capable of point of care loading of multiple
antibiotics and/or hydrophobic antifungals, for use as adjunctive therapy to reduce
bacterial and fungal wound contamination and biofilms in acute musculoskeletal trauma
injuries.
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CHAPTER 2
EFFECTS OF SODIUM ACETATE BUFFER ON CHITOSAN SPONGE
PROPERTIES AND IN VIVO DEGRADATION IN A RAT INTRAMUSCULAR
MODEL
Introduction
Musculoskeletal injuries are some of the most prevalent injuries in both civilian
and military populations and their infections can be difficult to treat, often resulting in
multiple surgeries, as well as increased patient morbidity, treatment time, and costs. 1 In
military operations, extremity injuries are the most frequent and many involve complex,
open fractures where bone is exposed to environmental contamination.2 Extremity
injuries are especially susceptible to multiple pathogenic, and sometimes multidrug
resistant bacteria, such as methicillin resistant Staphylococcus aureus (MRSA),
Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherichia coli.3,4 Up to 25%
of open fractures develop osteomyelitis, bone infection caused by bacteria or fungus, and
treatment failure rates are higher when either MRSA or P. aeruginosa are the infecting
organisms.5-7
The current standard of care for extremity wounds includes debridement and
irrigation of the affected area, as well as fracture stabilization, with serial debridement
and irrigation steps to follow.1 Systemic antibiotics are the current standard method of
prophylaxis and treatment for infections. Due to the avascular nature of traumatic wound
sites, delivery of inhibitory concentrations of antibiotics to affected tissue through the
bloodstream requires high dosing which carries risks ranging from allergic reaction to
ototoxicity or kidney failure.2-4 Local antibiotic delivery, used as an adjunctive therapy to
systemic dosing, can overcome the issues of sub-bactericidal antibiotic concentrations in
8

the avascular zones of wound sites by providing high levels of antibiotics directly to the
injured tissues.
Two of the most commonly used local antibiotic delivery systems in clinical
practice include antibiotic-loaded polymethylmethacrylate (PMMA) and calcium sulfate
(CaSO4). Antibiotic loaded PMMA beads provide a predictable release of antibiotic for
several weeks and reduce the infection rate in severe open fractures, but disadvantages
include the possibility for surgical removal and long term, sub-inhibitory antibiotic
concentrations which may encourage antibiotic resistant bacteria strains and/or biofilm
formation on the implant’s surface.5-10 CaSO4 is a degradable material with characteristic,
high initial antibiotic burst-release in the local wound site, elevated wound drainage, and
limited antibiotic choices and dosages.11-14
Porous chitosan sponges have been previously developed for rapid local drug
delivery as an adjunctive therapy during extremity wound debridement and irrigation. 15,16
These biocompatible sponges can be loaded at the point of care with physician selected
antibiotics and then release a high local dose of antibiotic to reduce bacterial levels. 15,16
However, one problem is that these sponges do not degrade quickly and can persist in the
wound, after the sponges have delivered the antibiotic. This delayed degradation is a
problem because remaining chitosan may act as a nidus for secondary infection.
One approach to increase chitosan degradation is to decrease crystallinity of the
chitosan polymer.24 Crystallization of the chitosan sponges occurs during sodium
hydroxide (NaOH) washes, used in the neutralization process. Using different solutions
for residual acid removal without inducing crystallization could help to increase sponge
degradation. In this investigation, sodium acetate buffers were used after a NaOH wash
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of the chitosan sponges and were compared to neutral sponges with NaOH washes only.
We hypothesized in vitro and in vivo analysis would reveal that modification of sponges
using the buffering step in fabrication would increase sponge degradation while not
affecting biocompatibility, compared to neutral chitosan sponges. The first aim of this
study was to evaluate whether the buffering procedure affected in vitro degradation and
biocompatibility, as well as thermal, crystalline, spectroscopic, and morphologic
properties. We then evaluated the in vivo degradation and biocompatibility of the
chitosan sponges in a rat dorsal muscle pouch model through both quantitative and
qualitative histological assessment of the implant sites.
Materials and Methods
Fabrication. Chitosan sponges were manufactured using previously described double
lyophilization methods.15,17,18 Chitopharm S chitosan was purchased from Chitinor AS
(Tromsoe, Norway) having a 82.5 ± 1.7 degree of deacetylation (DDA), 251 ± 17 kDa
weight-average molecular weight (MW) and 2.013 ± 0.145 polydispersity index. All
acids and buffer solutions were obtained from Fisher Scientific (Pittsburg, PA) First, the
chitosan was dissolved at 1% (w/v) in a 1% (v/v) blended acid solvent (3:1 ratio of lactic
to acetic acid). The dissolved chitosan solution was cast (250 mL) in an 11×20 cm
container, frozen at -20°C, and lyophilized in a Labconco (Kansas City, MO) FreeZone
2.5 Liter Benchtop Freeze Dry System. The dehydrated, acidic chitosan sponges were
then either neutralized in NaOH or neutralized in NaOH and soaked in one of two
different acetate buffer treatments to create neutralized or buffered sponges, respectively.
For the NaOH neutralization treatment, the sponges were rinsed in 250 mL of 0.6 M
NaOH for approximately seven minutes, washed with copious amounts of ultrapure water
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until a neutral pH was reached, and then re-frozen at -20°C and re-lyophilized. Based on
prior work and preliminary screening using multiple variations of acetate buffer pH,
concentration, and hydration times, the buffered sponges were fabricated by gently
compressing the hydrated sponge and then soaking the sponge in approximately 500 mL
of a 0.25 M acetate buffer at either 4.6 or 5.6 pH. After 30 minutes of hydration in the
buffer solution, excess buffer solution was removed and the buffered sponge was refrozen at -20°C and re-lyophilized. After the second lyophilization the neutral, 4.6 pH
buffered and 5.6 pH buffered chitosan sponges were stored in a desiccator cabinet until
subsequent analyses.
In Vitro Degradation. Degradation of neutralized, 4.6 pH, and 5.6 pH buffered chitosan
sponges was determined based on mass loss using a protocol previously reported. 18,19
Briefly, triplicate samples of each sponge formulation were trimmed to similar sizes and
weighed on a Mettler Toledo (Columbus, OH) XS205 Dual Range scale to establish an
initial weight. Samples were placed in a 125 mL Nalgene (Rochester, NY) container and
hydrated with 35 mL of 1 mg/mL 2× crystallized chicken egg white lysozyme and
penicillin (100 units/mL), streptomycin (100 mg/mL), amphotericin B (0.25 µg/mL),
both from MP Biomedicals (Solon, OH), in 1× phosphate buffered saline (PBS).
Degradation samples were placed on a rocking shaker in an incubator at 37°C and the
degradation solution was exchanged every 24 hours over 10 days. At each 24 hour
interval, three replicate chitosan sponge samples from each sponge variation were
removed from the degradation solution and rinsed in ultrapure water. Sponge samples
were then placed in a vacuum oven at 60°C for two days until dry and were weighed for a
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final sponge weight. The percent remaining of the sponge was calculated using equation
1.

Percent remaining

Sponge weight at

days

Initial dry sponge weight

(1)

The gentle, vacuum drying process eliminated the option of utilizing that individual
samples a second time, and therefore separate samples were analyzed for each replicate
and time point.
Molecular Weight. Molecular weight was determined by gel permeation
chromatography (GPC), using a TOSOH Bioscience (King of Prussia, PA) TSKgel
G5000PWxl column at 30°C, coupled with a Wyatt (Santa Barbara, CA) DAWN
HELEOS II multi-angle light scattering detector and Varian Prostar 450 refractive index
detector. Chitosan samples were dissolved at 1 mg/mL in the mobile phase solution of
0.15 M acetic acid and 0.1 M sodium acetate at pH 5. An injection volume of 50 µL and
a specific refractive index increment (dn/dc) for chitosan of 0.163 mL/g were used. 20
Crystallinity. X-ray diffraction (XRD) was used to characterize the crystal structure of
the raw chitosan material, as well as neutral, 4.6 pH, and 5.6 pH buffered chitosan
sponges. XRD patterns were determined using multiple scans from a Bruker AXS
(Madison, WI) Advanced D8 X-ray diffractometer with Kα Cu radiation source at 4 kV
and 4 mA over a 2θ range from 5° to 4 ° with a step size of . 5° and a time/step of .2
seconds.
Thermal Analysis. A Netzsch (Selb, Germany) 200 PC differential scanning calorimeter
(DSC) was used to evaluate the thermal properties of the three chitosan sponge
12

formulations and chitosan powder (n = 3). Samples were scanned from 40 to 400°C at
20°C/min in order to assess variations in endothermic and exothermic peak temperatures.
Spectral Analysis. In order to evaluate sponge differences, chitosan sponge sample
functional group chemistries were compared (n = 3) using attenuated total reflectance
Fourier transform infrared spectrometry (ATR-FTIR) with a ThermoScientific (Waltham,
MA) Nicolet iS10 FTIR spectrometer with a diamond ATR crystal. Absorbance spectra
were acquired using 64 scans with a resolution of 4 cm-1 and processed using the Thermo
Scientific OMNICTM Software Suite.
Morphology. Surface morphology of the three chitosan sponge formulations (n = 3) was
assessed using a FEI/Philips XL30 Environmental Scanning Electron Microscope at
15kV and samples sputter-coated with 30 nm of Au/Pd. Images were visually inspected
for differences between sponge groups such as surface texture and porosity.
Direct Contact Biocompatibility. A protocol modified from ASTM F813- 7 “Standard
Practice for Direct Contact Cell Culture Evaluation of Materials for Medical Devices”
was followed in order to assess the direct contact biocompatibility between the chitosan
sponge variations and normal human dermal fibroblasts (NHDF) purchased from Lonza
(Walkersville, MD). NHDF cells (passages 4 through 6) were seeded at 6×10 4 cells/mL
and allowed proliferate to confluence on BD Falcon (Franklin Lake, NJ) 12-well
polystyrene tissue culture plates in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and penicillin (100 units/mL),
streptomycin (100 mg/mL),amphotericin B (0.25 µg/mL), all purchased from Fisher
Scientific, under standard cell culture conditions (37°C and 5% CO2 atmosphere). Cell
culture medium was aspirated and refreshed with 1 mL of fresh medium before a single 8
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mm diameter test specimen (n = 5) of either a neutralized chitosan sponge, 4.6 pH
buffered chitosan sponge, 5.6 pH buffered chitosan sponge or a polyurethane sponge
(control) was gently placed in a well in direct contact with the cell monolayer. Cultures
were incubated for either one or three days before biocompatibility was assessed with the
Cell Titer-Glo® Luminescent Cell Viability assay (Promega, Madison, WI).The
luminescent signal, which corresponded to the amount of adenosine triphosphate and the
number of viable cells through a standard dilution of known concentrations of cells, was
recorded at 590 nm using a BioTek (Winooski, VT) FLx-800 Fluorescence Microplate
Reader.
In vivo Degradation. A total of 23, three month old male Sprague-Dawley rats (average
weight of 398 g) were utilized for this study. This pre-clinical study was approved by
institutional review boards at the University of Memphis (IACUC protocol #0720) and
the Army Medical Research and Material Command (Protocol DM 090455.02) and
followed guidelines set forth by both organizations. Rats were anesthetized with 2%
isoflurane in an environmental chamber and given a sub-cutaneous injection of carprofen
in the rat flank. The rat was prepared for sterile surgery with anesthesia maintained using
4 to 5% isoflurane. Two 1.5 cm incisions were made through the skin on each side of the
midline (4 incisions total). In each incision, a 1.25 cm pouch was created in the latissimus
dorsi muscle. One disc shaped implant, 9.5 mm in diameter and approximately 5 mm
thick, was implanted bilaterally in each muscle pouch. Test groups included gamma
irradiation sterilized (25.0 to 40.0 kGy dosage) neutralized chitosan sponge, 4.6 pH
buffered chitosan sponge, 5.6 pH buffered chitosan sponge and an absorbable gelatin
sponge (Gelfoam®, Pfizer, New York City, NY) as a positive control. Each rat received
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one of each implant, randomized among the four incision sites. After implantation, the
muscle incision was sutured while the skin was closed with one to three staples.
Carprofen was also administered for two days post-operatively. Ten rats were sacrificed
at the 4 and 10 day time points (n = 10). Satellite animals were sacrificed at the 14, 21
and 28 day time points (n = 1) for preliminary investigation of prolonged degradation.
Satellite animal degradation data was used for selecting degradation time points for future
in vivo studies. After each sacrifice the implanted region and surrounding tissue were
excised (see figure 5A) and placed in 10% phosphate buffered formalin for two days.
Tissue sections were then bisected across the implant for quantitative and qualitative
histological evaluation (paraffin-embedded and H&E stained). The percentages of sponge
and fibrous tissue in the defect area of the stained tissue sections were measured and
calculated using a Nikon inverted microscope Eclipse TE300 and BIOQUANT® OSTEO
II image analysis software, and cellular response was graded by three blinded reviewers.
Statistical Analysis. In vitro degradation testing was analyzed by least squares
regression. Thermal analysis was analyzed using one-way ANOVA with Tukey’s post
hoc analysis. In vitro biocompatibility samples were compared using an independent, two
sample t-test. Statistical analyses on the histological results were performed initially with
ANOVA and Holm Sidak post hoc analysis was used for the percent of fibrous tissue in
the defect and tissue response. Statistical significance level was set at α

. 5.

Results
In vitro degradation. The percentage of sponge remaining over time in the in vitro
degradation study is shown in Figure 1. Both the pH 4.6 and 5.6 buffered chitosan sponge
formulations exhibited significant differences in degradation, 71 and 44% respectively,
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from the neutral chitosan sponge. Although the pH 4.6 buffered chitosan sponge had a
lower percentage of sponge remaining, there was no significant difference between the
pH 4.6 and pH 5.6 sponge (p = 0.087). There was a significant decrease over time for the
4.6 pH buffered chitosan sponge (p = 0.0001) and 5.6 pH buffered chitosan sponge (p =
0.024) groups, but there was no change over time for the neutral sponge group (p =
0.592).

Figure 1. Results for the enzymatic-mediated degradation of neutral (♦), pH 5.6 buffered
(▲), and pH 4.6 buffered () chitosan sponges represented as mean ± standard deviation
for the percent by weight of the chitosan sponge remaining over time (n = 3).
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Molecular Weight, Crystallinity, and Thermal Analysis. X-ray diffraction spectra
(Figure 2) reveal differences between the chitosan powder, neutralized chitosan sponge,
and buffered chitosan sponges. Characteristic diffraction peaks for chitosan powder
appeared at 2θ of

.5° and 2 °. After manufacturing the powder into a neutralized

chitosan sponge, the 2θ of 2 ° peak was reduced to a minimum and subsequent
manufacturing into both buffered sponge versions eliminated this peak altogether. The
2θ

.5° diffraction peak intensity varied between the sponge groups, but all of the

group’s 2θ

.5° peak were lower than the chitosan powder’s.

Figure 2. Stacked x-ray diffraction (XRD) spectra in the 2θ range from 5° to 4 °of (top to
bottom) the chitosan powder, neutral chitosan sponge, pH 5.6 buffered chitosan sponge,
and pH 4.6 buffered chitosan sponge.
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The initial molecular weight and thermal analysis of chitosan powder and
neutralized and buffered chitosan sponges is shown in Table 1. Analysis of DSC data for
the chitosan samples revealed that endothermic and exothermic peaks appeared at 105111°C and 291-326°C, respectively. The endothermic peak corresponds to water loss and
the exothermic peak can be attributed to polymer decomposition, possibly of amine
units.21-23 The chitosan powder exhibited the highest exothermic peak temperature; after
processing chitosan into a neutral sponge, the exothermic peak temperature decreased (p
< 0.001). Buffering the chitosan sponges at pH 5.6 and 4.6 lowered the exothermic peak
temperature by 23.4 and 3 .2°C, respectively, from the neutral chitosan sponge’s peak
temperature (p < 0.001).

Table 1. Physicochemical Properties of Buffered and Unbuffered
Chitosan Sponges and Raw Material (n = 3).
Material

Molecular
Weight (kDa)

Thermal Analysis
Endotherm
Peak Temp.
(°C)

Exotherm
Peak Temp.
(°C)

Chitosan Powder

250.6 ± 16.60

111.6 ± 4.9

326.0 ± 0.1*

Neutral Chitosan
Sponge

172.0 ± 20.76

110.1 ± 2.5

321.4 ± 0.2*

pH 5.6 Buffered
Chitosan Sponge

220.1 ± 30.79

105.7 ± 2.4

291.2 ± 1.2*

pH 4.6 Buffered
Chitosan Sponge

171.0 ± 28.55

105.7 ± 1.9

298.0 ± 0.8*

*

represents p < 0.05 vs. all
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Spectral Analysis. As shown in Figure 3, several peaks characteristic of chitosan were
identified at the following wavenumbers: H-bonded, O-H stretching at the broad peak
centralized at 3350 cm-1; alkane, C-H stretching vibrations at 2910 and 2850 cm-1 ; amide
I band C=O stretching at 1640 cm-1; amine and amide II band N-H bending at 1550 cm-1;
C-H rocking at and just below 1400 cm-1 ; ether group C-O stretching at 1010 cm-1. All
peaks present are typical to chitosan functional groups and buffered groups showed
increased peak intensities and peaks shifting downward, indicative of acetate’s presence
in these sponges.

Figure 3. Stacked and averaged (n = 3) ATR-FTIR absorbance spectra for chitosan
powder, and neutral, pH 5.6 buffered and pH 4.6 buffered chitosan sponges.
19

Morphology. The morphology of the chitosan powder before processing into sponges
can be seen in Figure 4A, while the surface of the neutral, pH 5.6 and pH 4.6 buffered
chitosan sponges can be seen in Figures 4B, C, and D, respectively. Upon inspection, the
surfaces of both buffered chitosan sponge appear to have greater surface roughness than
the neutral sponge. The morphology of both the pH 5.6 and 4.6 buffered chitosan sponges
appears similar.
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Figure 4. Scanning electron microscopy representative images of chitosan powder at 30×
magnification (A) as well as the surface structure of the laminar sheets (at 50×
magnification) that comprise the neutral (B), pH 5.6 buffered (C), and pH 4.6 buffered
(D) chitosan sponges.

Direct contact biocompatibility. When normalized to the polyurethane sponge control
(Figure 5), each type of chitosan sponge caused significant decreases in biocompatibility
after one day of direct contact treatment (p ≤ . 4 ). However, after the three day
treatment end point, there were no significant differences between the sponge groups and
the control. Additionally, there was no cellular malformation, degeneration, sloughing, or
lysis and no reduction of the cell layer at the specimen perimeter upon microscopic
examination at either time point.
21

Figure 5. The percent cell viability (normalized to polyurethane sponge control) after
normal human dermal fibroblast direct contact cell viability testing of neutral, pH 5.6
buffered and pH 4.6 buffered chitosan, and polyurethane sponges after 1 and 3 days,
analyzed using Cell Titer-Glo Luminescent Cell Viability Assay. (n = 5, * represents p <
0.05 versus polyurethane sponge control)

In vivo degradation. Representative images from the in vivo degradation study are
shown in Figure 6, where Figure 6A shows an implanted sponge in a rat and Figure 6B
shows a bisected tissue block before histological processing. Histological evaluation of
the tissue revealed some implants to be completely degraded, (Figure 6C) while others
remained more intact (Figure 6D-F).
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Figure 6. This image set depicts the surgery site and sponge retrieval (A), a bisected
tissue section prepared for histological analysis (B), as well as representative H&E
stained tissue sections of the control gelatin (C), neutral chitosan (D), pH 5.6 buffered
chitosan (E) and pH 4.6 buffered chitosan sponge (F) surgery sites.
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The quantitative evaluation of the tissue histology for the percentage of implant
area per defect area is shown in Figure 7. After 4 and 10 days of sponge implantation in
the back muscle pouches of rats, none of the experimental groups, with regard to time
and sponge type, exhibited significant differences in percent of implant area per defect
area (p = 0.0856). Although not statistically different, all three types of chitosan sponge
had 5.1-5.6% and 0.3-1.6% lower average percentage of implant in the defect after 4 and
10 days than the control gelatin sponges. Both qualitative and quantitative evaluation of
the fibrous tissue present around the implants revealed a wide variability in fibrous tissue
response between surgical sites. After 10 days of implantation, the pH 5.6 buffered
sponges exhibited a 37.08% increase in fibrous tissue present in the defect (figure 8) over
the control gelatin sponges (p = 0.003).
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Figure 7. A histological analysis boxplot of the percent of gelatin, neutral chitosan, pH
5.6 buffered chitosan and pH 4.6 buffered chitosan sponge implants remaining in the
defect area, 4 and
days after surgery. (˟ represents a data point outside of the standard
deviation)
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Figure 8. A histological analysis boxplot of the percent of fibrous tissue present in the
defect area for gelatin, neutral chitosan, pH 5.6 buffered chitosan and pH 4.6 buffered
chitosan sponge implants, 4 and 10 days after surgery. (* represents p < 0.05 versus each
other, ˟ represents a data point outside of the standard deviation)
The only chitosan sponge type which demonstrated complete degradation in vivo
was the pH 4.6 buffered chitosan sponge (n = 1) after the satellite time point of 21 days
implantation (Table 2). The pH 4.6 buffered chitosan sponge was present after 28 days of
implantation in a different satellite animal, with 17.28% implant in the defect. There was
no percent implant data for the pH 4.6 and 5.6 buffered chitosan sponges at days 14, 14
and 21, respectively as they may have been lost in histological processing. Based on
similar photographs and tissue histology, the gelatin sponge is believed to have
completely degraded after 28 days of implantation.
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Table 2. Quantitative and qualitative analysis of satellite animal rat tissue histology after
14, 21, and 28 days of sponge implantation ,
Sponge
% Implant
% Fibrous
Average
Present in
Area/
Tissue/
Tissue
Tissue
Sponge
Time (days) Defect Area Defect Area Response
Block
Gelatin
14
13.36
33.06
1.7 ± 0.6
Yes
21
24
53.03
1.9 ± 0.1
Yes
28
0
0
0.3 ± 0.6
No
Neutral
14
8.81
13.22
1.7 ± 0.8
Yes
Chitosan
21
5.88
30.78
3.4 ± 0.7
Yes
Sponge
28
10.02
54.65
1.9 ± 0.4
Yes
pH 5.6
14
0
0
1.3 ± 0.6
Yes
Buffered
21
0
0
1.4 ± 0.4
Yes
Chitosan
28
4.59
24.75
4.3 ± 0.5
Yes
Sponge
pH 4.6
14
0
0
1.4 ± 0.5
Yes
Buffered
21
0
0
1.2 ± 1.0
No
Chitosan
28
17.28
36.82
3.8 ± 0.2
Yes
Sponge
Data is reported as mean ± standard deviation (n = 1 ) and tissue response is averaged
from three blinded reviewers.

After 4 days, tissue inflammatory response from the pH 5.6 and pH 4.6 buffered
chitosan sponges was significantly higher than the tissue response from gelatin sponges
(p = 0.029 and p < 0.001, Figure 9). After 10 days of implantation, tissue response was an
average of 1.98 to 2.11 grades lower from gelatin sponges than from all three types of
chitosan sponges (p < 0.001). Cellular response was not significantly different between
chitosan sponges, either neutral or buffered, at either time point. However, a highly
variable response was observed for all three histophotometry measures: percentage
implant, fibrous tissue, and tissue response grade.
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Figure 9. A histological analysis boxplot of the graded inflammatory response to the
gelatin, neutral chitosan, pH 5.6 buffered chitosan and pH 4.6 buffered chitosan sponge
implants, 4 and 10 days after surgery. Individual histological sections were scored (using
increments of 0.25) where 0 indicated a missing or minimal implant and minimal
response, ‒2 indicated mild leukocyte density, 2‒3 indicated a slightly elevated response
around the implant, 3‒4 indicated a moderate cell response, and 4‒5 indicated a high cell
density in and around the implant. (* represents p < 0.05 versus each other at each time
point, ˟ represents a data point outside of the standard deviation)

Discussion
Our results show that the incorporation of a sodium acetate buffer into a chitosan
sponge manufacturing process does significantly affect sponge material properties,
especially increasing in vitro degradation; however, it does not affect in vitro
28

biocompatibility or in vivo degradation in rat intramuscular tissue. Evidence that the
buffer affects in vitro sponge degradation is that both buffered sponge formulations
degraded significantly in mass, with 18 and 42% of the pH 4.6 and pH 5.6 buffered
chitosan sponges remaining after ten days, respectively, compared to the neutral sponge,
with 100% sponge remaining. The buffering process at pH 4.6 reduced the sponge’s
molecular weight by 0.5%, compared to the neutralized sponge. Although not significant,
this decrease is important because the literature indicates that in vivo degradation is
directly proportional to its molecular weight.24,25 While a decrease in molecular weight
was found in the chitosan sponges from the powder, the pH 5.6 buffered sponge exhibited
a surprising increase in molecular weight from the neutral sponges.
Chitosan’s DDA and crystallinity have both been previously shown to be
inversely proportional to chitosan’s degradation in vitro.34,35 Similar to other reported
findings,29 crystallinity analysis of the neutral and buffered sponges indicated that our
manufacturing, specifically the lyophilization process, decreased crystallinity from the
initial chitosan powder.
Thermal analysis of the chitosan powder and sponges indicated that the chitosan
lyophilization and neutralization procedure decreased exothermic peak temperatures,
corresponding to amine decomposition and a decrease in crystallinity.23 The exothermic
peak temperature decreased by 23.4°C and 30.2°C upon the addition of the buffering step
which may correspond to a decrease in molecular weight from chitosan powder, a
relationship shown in other investigations,30,36 similar to our findings of decreased sponge
molecular weight for the pH 4.6 buffered chitosan sponge and decreased crystallinity for
both buffered sponges.
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Our chemical analysis confirmed the various standard absorbance peaks of
chitosan were present in the sponges,26 along with the presence of acetate functional
groups in the buffered sponges as seen in other similar investigations. 27,28 Although
another researcher has reported the appearance of a carboxylic acid peak from chitosan at
approximately 1750 cm-1 Nunthanid et al did not see this carboxylic acid peak in either
chitosan flakes or chitosan acetate which corroborates our findings. 27
Morphological differences were seen in surface SEM images of the neutral and
buffered chitosan sponges. The apparent increase in surface roughness of both buffered
chitosan sponges, as compared to the neutral sponge, may be the physical manifestation
of changes in the chitosan’s molecular weight and crystallinity, and therefore may also be
related to an increase in in vitro degradation. Other studies of composite acid films
similarly produced increased surface roughness with increased acid incorporation in
chitosan films.40 Both buffered sponges exhibited similar morphology, indicating little
effect of the buffer’s pH on surface morphology. The similarities in chitosan sponge edge
and corner morphology of the neutral and buffered chitosan sponges indicate that all of
the sponges have a similar internal layering of chitosan layers, an example of which may
be seen in a previous publication.25
A review of the literature indicates that higher DDAs and molecular weight both
improve cytocompatibility and cell attachment. 29 All of the chitosan sponges exhibited
similar molecular weights and hence similar in vitro cell response. While cellular
compatibility levels in the literature fluctuate in direct contact assays largely due to the
positive control selection and exposure time, our results show similar fluctuations over
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time, where cell viability increased from one to three days, to those found for other
chitosan materials and applications.18,30
Chitosan is reported to be biocompatible and biodegradable29, however there have
been few studies performed using chitosan with only minimal modifications such as the
buffer procedure, administered by routes other than orally, for assessing biodegradation
and biocompatibility. In those studies that have been reported, chitosan in vivo
degradation is described as being dependent on molecular weight,43 and becomes
localized in the liver after intravenous injections. 44 In other studies, chitosan has been
reported as having minimal degradation after subcutaneous implantation,45 or rapid
degradation after use as a wound dressing. 23 These disparate findings led us to develop
this screening animal model as an evaluation method for our chitosan sponge device.
There was a wide variation in results, which lead to neither the neutral nor buffered
chitosan sponges showing significant differences in percentage of implant in defect from
the gelatin sponges, which served as a positive control of degradation. While there was
wide variability in the percent implant in defect of the gelatin sponges, more of the
gelatin sponges completely degraded than the chitosan sponges, confirming that sponge
degradation could be determined with this animal model.
Chitosan sponges exhibited statistically similar inflammatory tissue responses, but
there was an increase in inflammatory response in the pH 4.6 buffered sponges at day 4,
as compared to the pH 5.6 buffered chitosan sponges. However, this inflammatory
response difference narrowed at day 10 of implantation. The pH 4.6 buffered sponges
could be more acidic and would explain the increased inflammatory response than the pH
5.6 buffered sponges in the rat muscle tissue. This result is similar to the moderate
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inflammatory response observed in an in vivo study with Sprague-Dawley rats of chitosan
coated, via silane-gluteraldehyde linkage, to titanium with histological images seemingly
comparable to inflammatory responses as seen caused by the chitosan sponges. 46
Although there were no significant differences in percent implant in the defect
between the chitosan sponges after 10 days, which was a surprising finding in
comparison to the time course of the in vitro study, a few key differences could be seen in
the satellite animals (days 14, 21, and 28). Because the pH 4.6 buffered chitosan sponges
completely degraded after 21 days of implantation, this time point seems to be a more
realistic estimate of the time course of complete in vivo degradation. However, the
presence of the pH 4.6 buffered chitosan sponge after 28 days of implantation indicates
that in future extended in vivo studies, some of these buffered sponges might still remain
after 21 days. This degradation time may not be ideal because the chitosan sponges
typically release most of the loaded antibiotics early. 22
The available chitosan literature does not report many details on in vivo chitosan
degradation, and the in vivo degradation and elimination mechanism is still not well
understood. In the literature, there is molecular weight dependence for timely in vivo
degradation and elimination, while an increase in DDA and molecular weight may
provide for better biocompatibility.34,47,48 Our results indicate that the modified chitosan
sponge is biocompatible and is degrading in this screening model. From the chitosan
literature, the determination and achieving a desired in vivo degradation rate will require
balancing between the chitosan’s molecular weight, DDA, crystallinity, and the applied
manufacturing methods. Future work is needed and planned to define the in vivo
degradation profile of current chitosan sponge devices over an extended period of time so
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that the further development of the chitosan sponge may provide an alternative option for
the adjunctive therapy of contaminated musculoskeletal wounds.
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CHAPTER 3
PRELIMINARY EVALUATION OF CHITOSAN AND POLYETHYLENE
GLYCOL BLENDED SPONGES FOR THE IN VITRO LOCAL DELIVERY OF
AMPHOTERICIN B AND IN VIVO DEGRADATION IN A RAT
INTRAMUSCULAR MODEL
Introduction
Infection associated with musculoskeletal extremity injuries has a significant
impact on patient morbidity and mortality and can be a devastating complication. Open
extremity injuries are especially susceptible to multiple pathogenic, and sometimes drug
resistant, bacteria or fungi.1 Invasive fungal infections have recently become especially
troublesome for both military and civilian populations, with high mortality rates and high
healthcare costs.2-4 The British Military has recently reported higher rates of fungal
wound infections in casualties from the Helmand Province in Afghanistan.5 In a 2011
Trauma Infectious Disease Outcome Study, 36 cases of invasive fungal infections (IFI)
were found in Operation Enduring Freedom soldiers with blast injuries in Afghanistan
from June 2009 to December 2010, and 78% of these wounded soldiers with IFI required
lower extremity amputations.6 An outbreak of cutaneous mucormycosis was also
recently reported in victims from the 2011 tornado in Joplin, Missouri. 7,8 Apophysomyces
trapeziformis was identified in all 13 infected patients, 10 patients required admission to
intensive care, and 5 of these patients died. 7,8 Finally, invasive Candida infections are
the third most common cause of hospital-acquired bloodstream infections.9
The current standard of care for invasive fungal infections is systemic antifungal
delivery, and antifungals utilized for invasive fungal infection management include
triazoles, polyenes (amphotericin B), echinocandins, and flucytosine. 10 Although the
Infectious Disease Society of America advocates the use of voriconazole over traditional
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amphotericin B as the primary treatment of Aspergillus infections, both azole resistant
Aspergillus and Candida have emerged (as well as echinocandin resistant Candida).11
Amphotericin B is one of the most commonly used antifungals in clinical practice and
fungal resistance to the antifungal has not emerged over 50 years. 11 However, systemic
toxicity can be a concern with amphotericin B, so local delivery of amphotericin B is
highly desirable.12
While antibiotics have been studied extensively in local delivery, antifungals have
not been successfully locally delivered from as many degradable delivery systems
because of their hydrophobicity for loading and distribution. Amphotericin B has been
incorporated into a few local delivery systems, including polymethylmethacrylate
(PMMA) bone cement 12-14, a hydroxyapatite and chitosan composite15, a Pluronic® based
copolymer gel16, and dextran hydrogels17,18. Although PMMA is commonly used for
local antibiotic delivery, there is conflicting data on its release of amphotericin B.12-14
Goss and researchers found an absence of amphotericin B release from bone cement,
while Kweon et al. reported 0.05-0.45% release of the antifungal and Marra and
researchers found amphotericin B concentrations to be 3.2 µg/mL in surgical wound
fluid.12-14 Additionally, all of these local antifungal delivery systems are pre-loaded with
antifungal. A local degradable delivery system that is capable of rapid point of care
loading would allow the clinician to select the appropriate antimicrobial (or
antimicrobials) and dosage, based on each individual patient’s needs.
Previous research conducted at the University of Memphis has yielded a topical,
porous, degradable chitosan sponge that provides an adaptable antibiotic delivery system
in which tailored dosing and degradation can be achieved. 1-5 This system can be loaded
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with antibiotics immediately prior to use, allowing for clinician selected antibiotic
loading, as well as combination loading.1-5 Additional previous research has also shown
that using polyethylene glycol (PEG) as a solvent system for a hydrophobic fatty acid,
cis-2-decenoic acid, allows for point of care loading of the fatty acid into the chitosan
sponges.5 Polyethylene glycol is a water soluble polymer that exhibits protein resistance
and low toxicity and immunogenicity.6 PEG has been used to modify chitosan films,
fibers, and hydrogels, and chitosan can be blended or copolymerized with PEG. 6-9
Polyethylene glycol has also been utilized as a solvent system, either as liposomes or
nanoparticles, for amphotericin B in systemic delivery. 10-13
We hypothesized that creating chitosan/PEG blended sponges would result in
increased in vitro amphotericin B release, cytocompatibility, and in vitro and in vivo
sponge degradation, as compared to control chitosan sponges. The first aim of this study
was to evaluate the effect of adding PEG to the chitosan sponges on spectroscopic,
morphologic, thermal, and crystalline material properties, as well as in vitro degradation,
antifungal release, eluate fungal activity, and cytocompatibility. The second aim of the
study was to evaluate the in vivo degradation and biocompatibility of chitosan/PEG
sponges and control chitosan sponges in a rat dorsal muscle pouch model, using
qualitative and quantitative histological assessment of the implant sites.
Materials and Methods
Fabrication. Chitosan was purchased from Chinitor AS (Tromsway, Norway) with a
average molecular weight of 250.6 kDA and 82.46 ± 1.679 degree of deacetylation
(DDA). Polyethylene glycol (PEG) was obtained from Sigma Aldrich at two different
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molecular weights, 6,000 g/mol and 8,000 g/mol. Acetic acid and sodium hydroxide
(NaOH) were both purchased from Fisher Scientific (Pittsburgh, PA).
To make chitosan and PEG sponges, 0.5% (w/v) of PEG (6,000 or 8,000 g/mol)
was dissolved in a 1% (v/v) acetic acid in water solution. After PEG dissolution, 0.5%
(w/v) of chitosan was dissolved in the same solution. Chitosan sponges were
manufactured by dissolving 1% (w/v) chitosan in the 1% acetic acid solution. Solutions
were mixed on a stirplate for approximately one hour, and then 25 mL of the solution was
poured into 42 mL aluminum pans. The sponges were frozen for at least one hour at
-80°C and then lyophilized (lyo) in a LabConco (Kansas City, MO) FreeZone 2.5 Liter
Benchtop Freeze Dry System.
After the first lyophilization, the 1% chitosan sponges were neutralized in 0.6 M
NaOH, by soaking the sponges in the base solution for approximately 1-2 minutes and
then washing the sponges in large amounts of water until a neutral pH was reached. The
concentrations of NaOH solutions were determined through previous formulation testing.
Some of the chitosan/PEG sponges were neutralized in 0.25 M NaOH (the 2
lyophilization groups), while other chitosan/PEG sponges were not neutralized at all (the
1 lyophilization groups). After neutralization, the sponges were frozen again at -80°C
and lyophilized one last time. All sponges were sterilized via low dose gamma irradiation
at a 25-40 kGy dosage.
FTIR. Functional group chemistry differences between the sponges were evaluated using
attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR). A
ThermoScientific (Waltham, MA) Nicolet iS10 FTIR spectrometer with a diamond ATR
crystal was used to acquire the absorbance spectra (n = 3), using 64 scans with a
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resolution of 4 cm-1. The spectra were averaged and analyzed with the Thermo Scientific
OMNICTM Software Suite.
XRD. X-ray diffraction (XRD) was used to define the crystal structure of the chitosan
and chitosan/PEG sponges. A Bruker AXS (Maddison, WI) Advanced D8 X-ray
diffractometer was utilized to obtain X-ray diffraction patterns with a Kα Cu radiation
source at 40 kV and 40 mA. XRD data was obtained over a 2θ range from 5° to 40° with
a time/step of 0.2 seconds and a step size of 0.05°.
Thermal Analysis. Differential scanning calorimetry (DSC) was used to evaluate
differences in endothermic and exothermic peaks of the chitosan powder, PEG 6000,
PEG 8000, 1% chitosan sponges, and chitosan/PEG sponges. A Netzsch (Selb,
Germany) 200 PC differential scanning calorimeter was used to scan the samples (n = 3)
from 40 to 400°C at 20°C/min.
Morphology. Surface morphology of the chitosan and chitosan/PEG sponges was
assessed with a FEI/Philips XL30 Environmental Scanning Electron Microscope (SEM)
at 15 kV using samples sputter-coated with 30 nm of Au/Pd. SEM images (n = 3) were
qualitatively evaluated for differences between sponges such as surface texture and
porosity.
In Vitro Degradation. To analyze the enzymatic in vitro sponge degradation, sponges
were dried thoroughly and weighed. The sponges were placed in 125 mL Nalgene
(Rochester, NY) containers, along with 35 mL of 1 mg/mL 2 x crystallized chicken egg
white lysozyme, purchased from MP Biomedicals (Santa Ana, CA). The sponges in their
lysozyme solutions were placed on a shaker in an incubator at 37°C. The lysozyme
solution was completely refreshed every two days. After 2, 4, 8, and 10 days of
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degradation, sponge samples were removed from the lysozyme solution (n = 3), soaked
briefly in deionized water to stop any enzymatic degradation, dried thoroughly in a
vacuum oven at 60°C for two days, and then reweighed. This study was a destructive
study, so every time point represents a different sponge sample.
The percent sponge remaining over time was calculated according to equation 1,

Percent remaining

Sponge weight at

days

Initial dry sponge weight

(1)

Indirect Molecular Weight Measurement (Viscosity). To analyze the effect of in vitro
degradation indirectly on sponge molecular weight, the viscosity of sponges dissolved in
sodium acetate and acetic acid was measured. It was not possible to directly measure
molecular weight measurement of the chitosan and PEG blends though gel permeation
chromatography (GPC) because of different dn/dc values for chitosan and PEG.
Chitosan and chitosan/PEG sponges from the in vitro degradation 10 day time point
(n = 3) were dissolved in a solution of 0.1 M sodium acetate and 0.2 M acetic acid.
Chitosan and chitosan/PEG sponges that were not included in the degradation study were
also dissolved in the sodium acetate and acetic acid buffer (n = 3) and were considered a
zero day time point. A Brookfield Programmable DV-II + Viscometer with a CPE-40
cone spindle and circulating water bath at 25°C was used to measure the viscosity of
sponge solutions at 50 rpm.
Antifungal Elution. To determine if the chitosan/PEG sponges would deliver antifungals
locally in vitro, a 1 mg/mL solution of amphotericin B (Fisher Scientific) was created in
sterile Ultrapure water. The amphotericin B solution was shaken immediately prior to
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loading, and 10 mL of the antifungal solution was added to the sponges (n = 3). After
approximately one minute, the amphotericin B solution not absorbed by the sponge was
removed and measured. Twenty milliliters of sterile 1 x phosphate buffered saline (PBS)
was added to the sponges in Nalgene containers and they were then placed on a shaker in
an incubator at 37° C. After 1, 3, 6, 24, 48, and 72 hours of elution, four 1 mL samples
were removed from the sponge solution and the PBS was completely refreshed.
The concentration of amphotericin B in the eluates was measured via ultraviolet
visible spectroscopy. To prepare the insoluble amphotericin B samples, the eluates were
added 1:1 to dimethylsulfoxide (DMSO), purchased from Fisher Scientific. Highly
concentrated amphotericin B solutions, including the original 1 mg/mL solution, were
diluted in DMSO multiple times. Amphotericin B samples were read via absorbance at
389 nm in a Biotek (Winooski, VT) Synergy H1 plate reader and concentrations were
calculated using an amphotericin B standard curve.
Antifungal Activity. To determine if the amphotericin B released from the sponges
remained active against fungi, the amphotericin B eluate samples were lyophilized in foil
for one day. The samples were then dissolved in 50 μL of PBS and used to inoculate
blank discs. Standard concentrations of amphotericin B from 0 to 2.5 μg in 0.25 μg
increments were also used to inoculate blank discs. A 0.5 McFarland standard of Candida
albicans in sterile PBS was prepared and a cotton swab was used to streak a Mueller
Hinton agar plate in three different directions. An inoculated disc was added to each
plate and the plates were incubated overnight at 37°C. The zone of inhibition (ZOI) was
measured for each amphotericin B sample and a standard curve was determined. Zone of
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inhibition for each sample was also measured and compared to the standard curve to
determine sample concentration.
In Vitro Biocompatibility. The in vitro biocompatibility of both the chitosan/PEG
sponges and the antifungal eluates was tested on normal human dermal fibroblasts
(NHDFs), purchased from Lonza (Walkersville, MD). A protocol modified from ASTM
F813-07 “Standard Practice for Direct Contact Cell Culture Evaluation of Materials for
Medical Devices” was followed in order to assess the direct contact biocompatibility
between the chitosan sponge variations.14 Cells (passages 4 through 7) were seeded at
3.66×104 cells/mL (day one treatment) or 1.43 x 105 cells/mL (day three treatment) and
allowed to proliferate to near confluence on 12-well polystyrene tissue culture plates in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and penicillin (100 units/mL), streptomycin (100 mg/mL), and amphotericin
B (0.25 µg/mL), all purchased from Fisher Scientific, under standard cell culture
conditions (37°C and 5% CO2 atmosphere). Cell culture medium was aspirated and
refreshed with 1 mL of fresh medium, while chitosan, chitosan/PEG, and control
polyurethane sponges were soaked in pre-warmed, sterile 1 x PBS for approximately 20
minutes. A single 8 mm diameter test specimen (n = 5) was then gently placed in a well
in direct contact with the cell monolayer. Cultures were incubated for either one or three
days before biocompatibility was assessed with the Cell Titer-Glo® Luminescent Cell
Viability assay, purchased from Promega (Madison, WI).The luminescent signal, which
corresponded to the amount of adenosine triphosphate and the number of viable cells
through a standard dilution of known concentrations of cells, was recorded at 590 nm
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using a BioTek (Winooski, VT) Synergy H1 (day one treatment) or a BioTek FLx-800
Fluorescence Microplate Reader (day three treatment).
In Vivo Degradation. In vivo degradation and biocompatibility of the chitosan and
chitosan/PEG sponges was assessed in 13 three to four month old male Sprague-Dawley
rats. This in vivo study was approved by the institutional review board at the University
of Memphis (IACUC protocol #0728) and followed the IACUC guidelines. Rats were
anesthetized with 2% isoflurane in an environmental chamber and were maintained under
4-5% isoflurane while being prepared for sterile surgery. Two 1.5 cm incisions were
made through the skin on each side of the midline (4 incisions total) and a 1.25 cm pouch
was created in the latissimus dorsi muscle in each incision. One cylindrical implant, 9.5
mm in diameter and 5 mm in thickness, was implanted bilaterally in each muscle pouch.
Test groups included chitosan sponge, chitosan/PEG 6000 1 lyophilization (lyo),
chitosan/PEG 6000 2 lyo, and chitosan/PEG 8000 1 lyo sponges. Each rat received one of
each implant, randomized among four incision sites. The muscle incision was sutured and
the skin was closed with one to three staples. Carprofen was administered prior to surgery
and for two days post-operatively. Five rats were sacrificed at the 4 and 10 day time
points (n = 5), and satellite animals were sacrificed on the 14, 21 and 28 day time points
(n = 1). The degradation data from the satellite animals served as a preliminary indication
for longer degradation and for selecting degradation time points for future in vivo studies.
After sacrifice, the implanted region and surrounding tissue were excised, placed in 10%
formalin buffered phosphate (FBS) for two days, and then bisected across the implant for
quantitative and qualitative histological evaluation (paraffin-embedded and H&E
stained). Surgical defect areas of the stained tissue sections were measured as the

45

remaining sponge plus surrounding fibrous tissue using a Nikon inverted microscope
Eclipse TE300 and BIOQUANT® OSTEO II image analysis software. The area of
sponge and fibrous tissue were measured separately, divided by defect area, and
converted to a percentage. Qualitative histological evaluation was conducted by three
blinded reviewers based on cellular response. Histology was scored on a scale of 0 to 5
(low to high) in increments of 0.25, using a modified version of the Knodell Histological
Activity Index (HAI).15 Cellular response scores were 0 for no tissue for evaluation, 1 for
very mild leukocytic density, 2 for slightly more elevated cellular response, 3 for
moderate cellular response, 4 for high cell density in and around implant site, and 5 for
extremely high cellular response.
Statistical Analysis. Viscometry data was analyzed using one-way Analysis of Variance
(ANOVA) with Holm Sidak post hoc analysis. Thermal analysis was analyzed by oneway ANOVA with Holm Sidak post hoc analysis, except for the endothermic peak
temperatures and areas, which were analyzed using Kruskal-Wallis one-way ANOVA on
ranks with Tukey’s post hoc analysis. Antifungal elution, activity and cytocompatibility
data were analyzed using two-way ANOVA with Holm Sidak post hoc analysis. Twoway ANOVA was utilized to analyze the percent fibrous tissue in the defect and the
tissue response in the in vivo rat study. The percentage of implant in the defect in the rat
study was analyzed using Kruskal-Wallis one-way ANOVA with Dunn post hoc analysis.
Statistical significance level was set at α = 0.05.
Results
FTIR. Results from the FTIR analysis of the chitosan/PEG blended sponges and control
chitosan sponges are provided in Figure 1A, while Figure 1B shows the FTIR spectra of
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chitosan powder, PEG 6000, and PEG 8000. Characteristic peaks were seen in the 1%
chitosan sponges at 3290 (O-H stretching), 1643 (amide I C=O stretching), and 1557
(amide II N-H) cm-1.7,8,16 Characteristic C-O bending peaks were seen in PEG 6000 and
8000 at 1093, and peaks from the crystalline region of PEG were exhibited at 1278, 960,
and 840 cm-1.7,8
All blended sponges exhibited the characteristic chitosan peaks at 3357-3360
cm-1, and all peaks were shifted to higher wavelengths compared to the 1% chitosan
sponges. Characteristic chitosan peaks at approximately 1643 and 1557 cm-1 were also
seen in all blended sponges. All sponges and PEG also exhibited peaks at approximately
1145-1149 cm-1 (C-O stretching), where the peaks in the spectra of both 1 lyophilization
blended sponges, PEG 6000, and PEG 8000 were at lower wavelength than the 1%
chitosan sponge and 2 lyophilization blended sponges. 16 Both the chitosan/PEG 6000 1
lyo and 8000 1 lyo sponges exhibited the peaks seen in PEG at 1279 and 1099 cm-1, but
neither blended sponges with 2 lyophilizations nor the chitosan sponges exhibited these
peaks. All of the blended sponges, except for the chitosan/PEG 6000 2 lyo sponge,
showed the peak from PEG at 960-962 cm-1. All sponges exhibited the peak at 840-843
cm-1, but both blended sponges with 1 lyophilization and PEG had peaks with higher
absorbance than the 2 lyophilization blended and 1% chitosan sponges.
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Figure 1. Stacked and averaged (n = 3) ATR-FTIR absorbance spectra for (A) I.
chitosan/PEG 6000 1 lyo, II. chitosan/PEG 8000 1 lyo, III. chitosan/PEG 8000 2 lyo, IV.
chitosan/PEG 6000 2 lyo, and V. 1% chitosan sponges, and (B) I. chitosan powder, II.
PEG 6000, and III. PEG 8000.
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XRD. X-ray diffraction results (Figure 2A) reveal a difference between the chitosan
powder and all sponge types. The chitosan powder exhibited the typical crystalline peak
at approximately 20°, but this peak disappeared upon manufacturing the powder into
sponges, both in the control chitosan sponges or the chitosan/PEG blended sponges.
Additionally, the peak at approximately 12° in the chitosan powder decreases upon
sponge manufacturing, and the 1% chitosan, chitosan/PEG 6000 2 lyo, and chitosan/PEG
8000 1 lyo sponges displayed the smaller peaks. A very small peak can be seen in the
chitosan/PEG 6000 1 lyo sponge at 24°, which is a contribution from the crystalline peak
of PEG 6000 (seen in Figure 2B).
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Figure 2. (A) Stacked x-ray diffraction (XRD) spectra in the 2θ range from 5° to 40°of
(top to bottom) the chitosan powder, chitosan/PEG 6000 1 lyo sponge, chitosan/PEG
8000 2 lyo sponge, chitosan/PEG 6000 2 lyo sponge, 1% chitosan sponge, and
chitosan/PEG 8000 1 lyo sponge, and XRD spectra in the 2θ range from 5° to 40° of (B)
PEG 6000, and (C) PEG 8000.
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DSC. The DSC data for the chitosan/PEG and chitosan sponges, and chitosan, PEG
6000, and PEG 8000 powder is provided in Table 1.

Table 1. Differential scanning calorimetry results of chitosan/PEG and chitosan sponges,
as well as chitosan, PEG 6000, and PEG 8000 powder.
Endothermic Peak
Exothermic Peak
Sample
Temperature Height
Area
Temperature Height
Area
(°C)
(mW/mg) (J/g)
(°C)
(mW/mg) (J/g)
Chit/PEG
56.0 ± 1.0§γ 1.6 ± 0.2
-70 ±4.4 313.7 ±
0.9 ±
93.5 ±
6000 1 Lyo
0.9*†
0.02*†
11.8*†
Chit/PEG
110.8 ± 4.8 1.1 ± 0.1
-191.8 ± 319.5 ± 1.1 2.3 ± 0.3
169.7 ±
6000 2 Lyo
28.9
22.0
*†
Chit/PEG
58.6 ± 0.6
1.6 ± 0.1
-79.2 ±
315.4 ±
1.0 ± 0.1
94.8 ±
*†
8000 1 Lyo
6.3
2.0
7.7*†
Chit/ PEG 122.9 ± 9.2γ 1.1 ± 0.1
-200.7 ± 319.1 ± 0.2 2.3 ± 0.2
168.1 ±
8000 2 Lyo
9.5
2.9
1%
126.7 ± 7.8§ 1.1 ± 0.04 -210.5 ± 319.2 ± 1.1 2.1 ± 0.1
160.1 ±
Chitosan
12.0
5.4
Sponge
Chitosan
111.6 ± 4.9 1.0 ± 0.1
-181 ±
326.0 ± 0.1‡ 3.3 ± 0.1‡ 178.7 ±
powder
28.3
8.6
PEG 6000 68.1 ± 0.5
6.1 ± 0.4
-201.6 ± N/A
N/A
N/A
9.5*†
PEG 8000 67.9 ± 0.4
6.6 ± 0.6
203.2 ± N/A
N/A
N/A
6.9*†
§
and γ indicate p < 0.05 vs. each other,* represents p < 0.05 versus all others except †, ‡
indicates p < 0.05 versus all others

Analysis of the thermal data revealed that endothermic and exothermic peaks
appeared at 56-126°C and 313-319°C in the sponges and powder samples. The
endothermic peak can be attributed to water loss, while the exothermic peak corresponds
to the decomposition of amine units.17-19 Because the PEG 6000 and 8000 powder
samples do not have amine units, both are lacking the exothermic peak. The chitosan
powder had the highest exothermic peak temperature, but after processing the chitosan
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into a 1% chitosan sponge, the exothermic peak temperature decreased by 6.8°C (p <
0.001). The chitosan/PEG 2 lyo sponges also exhibited similar exothermic peak
temperatures to the 1% chitosan sponge. However, the chitosan/PEG 6000 and 8000 1
lyo sponges exhibited 5.44°C and 3.77°C lower exothermic peak temperatures than the
1% chitosan sponge (p < 0.001 and p = 0.008). Additionally, the height and area of the
exothermic peaks in the chitosan/PEG 1 lyo sponges also decreased significantly from the
chitosan/PEG 2 lyo and 1% chitosan sponges. The chitosan/PEG 1 lyo sponges also
exhibited lower endothermic peak temperatures and areas than the chitosan/PEG 2 lyo
sponges, 1% chitosan sponges, and chitosan powder.
SEM. The morphology of the cross-sections of the 1% chitosan sponges and
chitosan/PEG blended sponges can be seen in Figure 3A-E, while the surface structure of
the 1% chitosan sponges and chitosan/PEG blended sponges can be seen in Figure 3F-J.
The cross-sections of all sponges do not appear to be significantly different. However, the
surface of the 1% chitosan sponge appears to have the greatest surface roughness, with
the chitosan/PEG 6000 1 lyo and chitosan/PEG 8000 1 lyo sponges exhibiting a slight
decrease in surface roughness. In the chitosan/PEG 8000 2 lyo sponge, only a few visible
pores can be seen, while none can be seen in the chitosan/PEG 8000 1 lyo sponge.
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Figure 3. Representative scanning electron microscopy of sponge cross sections at 30×
magnification: (A) 1% chitosan, (B) chitosan/PEG 6000 1 lyo, (C) chitosan/PEG 6000 2
lyo, (D) chitosan/PEG 8000 1 lyo, and (E) chitosan/PEG 8000 2 lyo sponges, as well as
sponge surface structure at 30× magnification of (F) 1% chitosan, (G) chitosan/PEG 6000
1 lyo, (H) chitosan/PEG 6000 2 lyo, (I) chitosan/PEG 8000 1 lyo, and (J) chitosan/PEG
8000 2 lyo sponges.
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In vitro degradation and viscosity. Results from the in vitro degradation study of the
chitosan/PEG blended sponges and control chitosan sponges are provided in Figures 4A
and 4B. The chitosan/PEG 6000 1 lyo, chitosan/PEG 6000 2 lyo, and chitosan/PEG
8000 1 lyo sponges exhibited significant differences in degradation, 58.99, 31.11, and
94.18% respectively, than the control chitosan sponge, as well as 49.37, 21.59, and
84.66% less sponge remaining than the chitosan/PEG 8000 2 lyo sponge (Figure 4A).
There was no significant decrease in remaining sponge over time for any of the
chitosan/PEG sponges.
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Figure 4.(A) Percent sponge remaining (mean ± standard deviation) of chitosan/PEG
6000 1 lyo (○), chitosan/PEG 6000 2 lyo (■), chitosan/PEG 8000 1 lyo (▲),
chitosan/PEG 8000 2 lyo (♦), and 1% chitosan () sponges after 2, 4, 8, or 10 days of in
vitro enzymatic-mediated degradation (n = 3), where at each time point, * indicates p <
0.05 versus 1% chitosan, † denotes p < 0.05 versus chitosan/PEG 8000 2 lyo, ** indicates
p < 0.05 versus all, and ‡ represents p < 0.05 versus all except §. (B) Brookfield viscosity
measurements of sponges dissolved in 0.1 M sodium acetate and 0.2 M acetic acid before
degradation (day 0) and after enzymatic-mediated degradation (day 10), where * denotes
p < 0.05 pairwise.
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Viscosity measurements were used in order to indirectly evaluate possible
molecular weight changes of the blended polymer sponges after degradation; direct
molecular weight measurements were not possible through GPC. All of the sponges,
except for the chitosan/PEG 6000 2 lyo sponges, exhibited a decrease in viscosity from
day 0 to day 10 of degradation (Figure 4B), although only the chitosan/PEG 8000 2 lyo
sponge exhibited a statistically significant difference (p = 0.014).
In Vitro Amphotericin B Elution. The in vitro amphotericin B release from the
chitosan/PEG and chitosan sponges is reported in Figure 5. The average concentrations
of amphotericin B released from all sponges after 1 and 3 hours were all above the
minimum inhibitory concentration (MIC) for Candida albicans, but not for all later time
points. The chitosan/PEG 6000 1 lyo sponge was the only sponge formulation to release
amphotericin B at levels above the C. albicans MIC throughout the entire 72 hour
elution. The chitosan/PEG 6000 and 8000 2 lyo sponges released average amphotericin
B concentrations above the MIC at 72 hours, but not for all earlier time points. After 1
hour of elution, the chitosan/PEG 6000 1 lyo sponge released 20.41, 11.88, 19.34, and
23.60 more μg/mL of amphotericin B than the chitosan/PEG 6000 2 lyo, chitosan/PEG
8000 1 lyo, chitosan/PEG 8000 2 lyo, and 1% chitosan sponges, respectively. The
chitosan/PEG 8000 1 lyo sponge also released 8.53, 7.46, and 7.91 more μg/mL of
antifungal after 1 hour than the chitosan/PEG 6000 2 lyo, chitosan/PEG 8000 2 lyo, and
1% chitosan sponges, respectively. The cumulative percent release of loaded
amphotericin B after 72 hours was determined to be 12.4 ± 3.8, 5.3 ± 3.6, 5.2 ± 0.3, 5.4 ±
2.1, and 7.7 ± 2.2% for the chitosan/PEG 6000 1 lyo, 6000 2 lyo, 8000 2 lyo, and 1%
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chitosan sponges, respectively. While the chitosan/PEG 1 lyo, and 1% chitosan sponges
exhibited significant differences in antifungal elution over time, the chitosan/PEG 2 lyo
sponges did not release significantly different concentrations of amphotericin B over
time.
Antifungal Activity. Results from the antifungal activity zone of inhibition assay can be
seen in Figure 6, reported as amphotericin B concentration in μg/mL. All of the selected
amphotericin B eluates tested in the assay had sufficient corresponding activity on
Candida albicans, except for the eluates from the 1% chitosan sponges. Some of the
amphotericin B eluates released from the 1% chitosan sponges that were measured at
levels above the C. albicans MIC did not inhibit growth of C. albicans in the ZOI assay.
In the ZOI assay, the eluates from the chitosan/PEG 6000 1 lyo and 8000 1 lyo sponges
had the highest C. albicans zone of inhibition and corresponding amphotericin B
concentration, and were both significantly different from the 1% chitosan sponges after 6
(p = 0.004 and p = 0.006 ) and 48 hours (p = 0.006) of elution.
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Figure 5. Amphotericin B released in vitro in µg/mL (mean ± standard deviation) from
sponges over time and the minimum inhibitory concentration of amphotericin B for
Candida albicans, where * represents p < 0.001 versus chit/PEG 6000 1 lyo 1 hour time
point, † denotes p < 0.003 versus chit/PEG 8000 1 lyo 1 hour time point, δ indicates p <
0.05 versus 1% chitosan 1 hour time point, ** represents p < 0.001 versus all sponge
groups within the time point, and †† denotes p < 0.007 versus all sponge groups within
the time point except for ‡.
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Figure 6. Results from antifungal activity zone of inhibition assay using selected
amphotericin B eluted from chitosan/PEG and 1% chitosan sponges, where * indicates
p < 0.05 versus control 1% chitosan sponge.

Cytocompatibility. As seen in Figure 7, each type of sponge caused significant
decreases in cytocompatibility from the control polyurethane sponge, where the control
was considered 100% cell viability, after one day of direct contact treatment (p < 0.014).
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Figure 7. Direct contact biocompatibility normalized to polyurethane sponge control,
represented in mean percent cell viability ± standard deviation, of normal human dermal
fibroblasts after exposure to polyurethane, chitosan/PEG, and 1% chitosan sponges for
one and three days, analyzed using Cell Titer-Glo® luminescent assay (* indicates p <
0.05 versus polyurethane sponge control)

After 1 day, the 1% chitosan sponge and chitosan/PEG 8000 2 lyo sponges
exhibited the largest decreases in percent cell viability, with 39 and 28.57% reduction in
cell viability from the polyurethane control, respectively. Upon microscopic examination
after one day of treatment, both the 1% chitosan and chitosan/PEG 8000 2 lyo sponges
exhibited slight cellular malformation changes in some fibroblasts, while the other
blended sponges did not cause any visible changes to the cells from the control. However,
after three days of treatment, there were no significant differences between any of the
sponges and the polyurethane sponge control. After three days of treatment, the cellular
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morphology that was visible after day one for some of the sponges was no longer present.
Additionally, these cytocompatibility evaluations found no sloughing, lysis, or reduction
of the cell layer at either time point.
In Vivo Degradation and Biocompatibility. Data from the quantitative and qualitative
evaluation of the rat tissue histology is shown in Figures 8-10. The percentage of implant
area per defect area after 4 and 10 days of implantation is shown in Figure 8, but none of
the experimental groups, with regard to time, exhibited significant differences (p =
0.449). The control 1% chitosan sponges and chitosan/PEG 6000 1 lyo sponges did
exhibit significant differences in percent implant after 4 days of implantation (p = 0.001).
None of the sponges degraded completely after 10 days. Quantitative and qualitative
evaluation of fibrous tissue present around the sponges revealed a wide variability
between surgical sites (Figure 9). Additionally, there were no statistically significant
differences in percent fibrous tissue area per defect area between any of the sponges, with
regard to sponge or time (p = 0.130 and p = 0.723).
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Figure 8. Histological analysis boxplot of the percentage of sponge implants present in
the defect area, 4 and 10 days after surgery (+ and ○ represents the mean and a data point
outside of the standard deviation, respectively)
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Figure 9. Histological analysis boxplot of the percentage of fibrous tissue present in the
defect area (+ and ○ represents the mean and a data point outside of the standard
deviation, respectively)
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After 4 days of implantation, the chitosan/PEG 8000 1 lyo sponge exhibited the
lowest average tissue response of the blended sponges (Figure 10), although not
statistically different (p = 0.336). Similar to the implant percentage results, the
chitosan/PEG 6000 1 lyo sponge displayed the highest average tissue response of all the
sponges. After 10 days of implantation, the average tissue response increased by 5, 4, 5,
and 72% for the 1% chitosan, chitosan/PEG 6000 1 lyo, chitosan/PEG 6000 2 lyo, and
chitosan/PEG 8000 1 lyo sponges, respectively.
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Figure 10. Histological analysis boxplot of the average graded inflammatory response
from three blinded reviewers (+ and ○ represents the mean and a data point outside of the
standard deviation, respectively)
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In the satellite animals, none of the chitosan/PEG blended sponges nor the
chitosan sponges degraded completely after 14, 21, or 28 days (Table 2). However, the
chitosan/PEG sponges exhibited decreases in percent implant from 10 days to 28 days,
and the chitosan/PEG 6000 2 lyo sponge demonstrated the largest decrease in implant
percentage with an 88.77% reduction in percent implant from 10 to 28 days of
implantation. While there is no data for the percentage of chitosan/PEG 6000 1 lyo
sponge in defect after 14 days, the sponge was present in the original tissue block, so it is
believed to have been lost in histological processing.

Table 2. Quantitative and qualitative analysis of satellite animal rat tissue histology after
14, 21, and 28 days of sponge implantation

Sponge
Chitosan/PEG
6000 1 Lyo
Sponge

Time (days)
14
21
28

% Implant
Area/ Defect
Area
0
27.55
9.58

% Fibrous
Average
Tissue/ Defect Tissue
Area
Response
0
1.33 ± 0.14
27.55
2.5 ± 0.5
9.58
2.08 ± 1.01

Sponge
Present in
Tissue Block
Yes
Yes
Yes

Chitosan/PEG
6000 2 Lyo
Sponge

14
21
28

14.25
5.78
1.76

17.53
15.51
5.01

3.08 ± 0.88
2.75 ± 0.90
1.67 ± 1.61

Yes
Yes
Yes

Chitosan/PEG
8000 1 Lyo
Sponge

14

8.52

10.33

3.33 ± 0.58

Yes

21
28

14.72
8.13

24.96
12.05

3.5 ± 0.25
1.83 ± 1.04

Yes
Yes

1% Chitosan
Sponge

14
21

4.02
7.08

27.9
28.19

4 ± 0.25
3.75 ± 0.43

Yes
Yes

28
21.58
23.6
2 ± 0.5
Yes
Data is reported as mean ± standard deviation (n = 1) and tissue response is averaged
from three blinded reviewers.
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Discussion
These experimental results demonstrate that blending chitosan with polyethylene
glycol in sponge form does significantly affect sponge material properties, amphotericin
B elution, antifungal activity, and in vivo degradation in rat intramuscular tissue.
However, blending does not affect in vitro cytocompatibility or in vivo biocompatibility
in rat tissue. The presence of characteristic PEG peaks at 1279, 1099, 960, and 842 cm-1
in both 1 lyo chitosan/PEG blended sponges confirm the presence of PEG in the sponges.
Although these peaks are not present in the 2 lyophilization blended sponges, the peak
shift to lower wavelength at 842 cm-1 in the 2 lyophilization sponges, as compared to 843
cm-1 in the 1% chitosan sponge, indicates the possibility of residual PEG and possible
interaction between chitosan and PEG. The chitosan/PEG 8000 2 lyo blended sponge also
exhibited the characteristic PEG peak at 962 cm-1, which indicates this blended sponge
may have more PEG present in the sponge than the 6000 2 lyo sponge, which did not
exhibit the peak. The FTIR spectra of the blended sponges in this study did not
demonstrate a disappearance or shift of the amide I band to lower wavelength, as reported
in previous research.7,8 However, all blended sponges, except for the 6000 2 lyo sponge,
exhibited decreased absorbance of the amide I peak at 1643 cm-1. The chitosan/PEG 1 lyo
sponge also demonstrated both a shift of the amide II N-H peak at 1557 cm-1 to lower
wavelength and increased absorbance compared to the chitosan sponge, which has also
been confirmed by previous studies.7,8
Analysis of the XRD spectra revealed that the chitosan powder exhibited a
hydrated crystalline peak at 2θ = 10° and a sharp hydrated crystalline peak at 2θ = 20°,
indicating the presence of anhydrous chitosan crystal structure. 20 After chitosan
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dissolution and lyophilization, the crystalline peak at 20° disappeared and the 10° peak
decreased and became broader, suggesting a large loss in helical crystalline forms. 21
Additionally, the increase of the peak and its sharpness at 2θ = 7° in the sponges from the
powder indicates there could be some reordering of the polymer chains. Because of the
increased 10° peak in both the chitosan/PEG 6000 1 lyo and 8000 2 lyo sponges and the
presence of the small PEG crystalline peak at approximately 24° in the chitosan/PEG
6000 1 lyo sponge, both of these blended sponges appeared to exhibit increased
crystallinity from the other blended and control chitosan sponges. The chitosan/PEG
6000 2 lyo and 8000 1 lyo sponges only showed a slightly reduced 10° peak from the
chitosan sponge, which is similar to previously reported research on chitosan/PEG
blended fibers7 and films16. Similar to this study, Wang et al. also found chitosan/PEG
blended fibers to be absent of PEG crystalline peaks in XRD spectra. 7
Thermal analysis of the chitosan powder, sponges, and chitosan/PEG blended
sponges indicated that the chitosan double lyophilization and neutralization procedure
decreased exothermic peak temperatures, which corresponded to amine decomposition. 19
Additionally, the one lyophilization procedure for some of the chitosan/PEG sponges
decreased the exothermic peak temperatures even further, by up to 5.5°C from the
chitosan powder, and decreased the exothermic peak height and area as well. This shift of
the exothermic peak to lower temperatures in the 1 lyo sponges is similar to previously
reported findings that, with increasing PEG content in chitosan and PEG blended films,
the exothermic peak temperature shifted to lower temperatures. 16 Additionally, the
decreased endothermic peak temperatures (56.03 and 58.57°C) in the chitosan/PEG 1 lyo
sponges can be attributed to the melting temperature of PEG 6000 and 8000,
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approximately 68°C. The shift to even lower endothermic peak temperatures can be
explained by increased lattice defects due to partial miscibility of the noncrystalline
phase.16,22
Morphological differences were seen in surface SEM images, but not crosssection images, of the chitosan/PEG and chitosan sponges. The smoother appearance of
the chitosan and PEG blended sponges, as compared to the 1% chitosan sponges, may
indicate the compatibility of two polymers in a blend. The chitosan/PEG sponges’
morphologies agrees with previously reported research that chitosan/PEG blended films 6
and fibers7 exhibited smooth and nonporous surfaces6 and smooth and homogenous cross
sections7, respectively.
In vitro degradation is one of the sponge material properties affected by the
addition of PEG, molecular weight of PEG, and number of lyophilizations. The addition
of PEG 6000 to the chitosan sponges, as well as the use of only 1 lyophilization, caused
the chitosan/PEG 6000 1 and 2 lyo and chitosan/PEG 8000 1 lyo sponges to degrade
significantly in mass, with 1-75% sponge remaining over ten days, compared to 82.0497.46% and 99-100% sponge remaining in the chitosan/PEG 8000 2 lyo and control
chitosan sponges. As expected, the degradation of the blended chitosan/PEG sponges in
this study is higher than the degradation that Tanuma et al. reported for PEG crosslinked
chitosan films, 7% weight loss after 8 days of lysozyme mediated degradation. 23 While
molecular weight could not be directly measured through GPC methods, the sponges’
slight decrease in viscosity after ten days of degradation demonstrates there might be a
slight decrease in sponge molecular weight after degradation; however, the viscosity of
the blended sponges did not decrease as much as the 55% reduction in specific viscosity
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of PEG grafted chitosan solutions in 7.5 mg/mL lysozyme reported in a previous study. 24
Although the chitosan/PEG 6000 and 8000 1 lyo sponges exhibited the lowest percent
sponge remaining in the in vitro degradation study, the smoother surfaces of the blended
sponges visualized by SEM, as compared to the chitosan sponge, indicates that surface
roughness may not be related to increased in vitro degradation.
Differences in amphotericin B elution were seen in the sponges upon adding PEG
to the chitosan sponges and using only one lyophilization. The chitosan/PEG 6000 1 lyo
sponge released 12.43 ± 3.81% of loaded amphotericin B after 72 hours, while the
chitosan/PEG 6000 2 lyo sponge released 5.27 ± 3.55% of loaded amphotericin B over
the same time frame. While the chitosan/PEG 8000 1 lyo sponge only released 5.22 ±
0.31% of loaded antifungal over 72 hours, the sponge released significantly more
amphotericin B after one hour of elution than the other blended sponges. Although the
sponges are still retaining amphotericin B, all of the sponges released more antifungal in
vitro than what has been previously reported for amphotericin B loaded bone cement,
0.45 and 0.05% with and without a poragen25 or 0.03% release26 of loaded amphotericin
B. As expected, the percent cumulative release from the post-loaded chitosan/PEG
blended sponges was less than the 60% amphotericin B release after 2 days from a
preloaded Pluronic® based multi-block copolymer gel.27
Although the control chitosan sponges released more amphotericin B than some
of the blended sponges with 7.68 ± 2.20% cumulative release, many of these antifungal
eluates did not maintain sufficient activity against C. albicans. Whereas, all the tested
amphotericin B elution samples from the chitosan/PEG 6000 and 8000 1 lyo sponges and
all but three elution samples from the chitosan/PEG 6000 2 lyo sponges remained active
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against C. albicans. The active amphotericin B eluates from the chitosan/PEG sponges
are similar to previously reported active amphotericin B eluates from PMMA bone
cement.28 The antifungal activity ZOI assay results in this current study provide an
indication that the addition of PEG to the chitosan sponges is an improvement for
antifungal elution and activity over the unblended chitosan sponges.
As expected, the chitosan/PEG blended sponges did not elicit any significant
cytotoxic effects on normal human dermal fibroblasts. Previous research has shown that
adding PEG to chitosan films enhanced protein adsorption and cell adhesion, growth, and
proliferation.6 The chitosan/PEG 8000 2 lyo sponge’s slight decrease in cell viability
after one day of treatment indicates there may be more similarities between the
chitosan/PEG 8000 2 lyo sponge and control chitosan sponge than the other blended
sponges. The differences in cytocompatibility found over time for all sponges in this
study are also similar to previous results reported for other chitosan applications. 3,29
While adding PEG to the chitosan sponges resulted in increased in vitro
degradation, the chitosan/PEG sponges did not exhibit increased in vivo degradation in
the rat intramuscular model compared to the chitosan sponges. However, similar to the in
vitro degradation results, the chitosan/PEG 8000 1 lyo sponge demonstrated the lowest
percent implant in the defect after ten days of implantation. Conversely, the increased in
vivo degradation in the chitosan/PEG 6000 2 lyo sponge over the chitosan/6000 1 lyo
sponge, whereas the opposite was shown in vitro, demonstrates the difficulty of
translating from in vitro studies to in vivo. Although chitosan has been reported to be
biodegradable and biocompatible, wide data variations exist in the literature; for example,
one study reported chitosan to have minimal degradation after subcutaneous
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implantation, while other researchers showed a chitosan wound dressing to have rapid
degradation.2,30,31 There was also wide variation in results in this study which led to
none of the blended sponges showing significant decreases, either in percent implant and
percent fibrous tissue, from the control chitosan sponges.
Chitosan/PEG and chitosan sponges exhibited statistically similar inflammatory
tissue responses, but the chitosan/PEG 6000 1 lyo sponge demonstrated increased
inflammatory response after 4 days of implantation and slightly higher average tissue
response after 10 days. These results demonstrate that, in addition to reduced in vivo
sponge degradation, the chitosan/PEG 6000 1 lyo sponge exhibits a more acute
inflammatory response than the other two blended sponges; these findings have lead us to
eliminate this blended sponge formulation from future research. The average
inflammatory response for the control chitosan sponges was also higher than all of the
chitosan/PEG blended sponges after 10 days of implantation. However, the
inflammatory responses from all of the sponges are still lower than the tissue response
from the sutures and are similar to reported moderate inflammatory responses from
chitosan coated titanium pins implanted in Sprague-Dawley rats.32
Although none of the sponges degraded within 28 days, all of the blended sponges
appeared to be degrading over time and a few important differences can still be seen in
the satellite animal data. After 28 days, the chitosan/PEG 6000 2 lyo sponge was
surprisingly the most degraded of the sponge types, and was almost completely degraded.
Even though these results are just in one animal for each sponge, the data still provides an
indication of in vivo degradation trends.
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There has not been much research on local antifungal delivery systems, and many
of the local delivery systems that exist release too little antifungal or are not designed to
degrade. In previous research, biocompatible polyethylene glycol (PEG) has been
utilized to deliver the hydrophobic antifungal, amphotericin B. Our results indicate that
blending chitosan and PEG into sponges creates biocompatible and degradable sponges
capable of point of care amphotericin B loading and in vitro release that perform better
than our previously developed chitosan sponges. Future work is needed to extend the in
vivo study to better define the time of in vivo degradation. Other studies are also planned
to study the loading and release of both antifungals and antibiotics, separately and
combined, from the blended sponges so that the further development of the chitosan/PEG
blended sponges may provide a truly customizable adjunctive therapy for bacterial and
fungal contaminated musculoskeletal wounds.
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CHAPTER 4
CHARACTERIZATION OF LOCAL DELIVERY WITH AMPHOTERICIN B
AND VANCOMYCIN FROM MODIFIED CHITOSAN SPONGES AND
FUNCTIONAL BIOFILM PREVENTION EVALUATION
Introduction
Musculoskeletal trauma is one of the most prevalent types of injuries in the
United States; more than three out of five of the unintentional injuries occurring annually
in the U.S. are musculoskeletal injuries. 1,2 Musculoskeletal extremity injuries are
especially susceptible to multiple pathogenic, and sometimes drug resistant bacteria and
fungi, such as methicillin resistant Staphylococcus aureus (MRSA), Pseudomonas
aeruginosa, Acinetobacter baumannii, Escherichia coli, Aspergillus spp., and Candida
albicans. 2, 3 These infection complications can increase morbidity and/or mortality, as
well as increase hospitalization costs and stays. 4 Although bacteria typically cause the
majority of musculoskeletal infections, invasive fungal infections (IFI) have recently
caused significant problems for both the British and United States military; the U.S.
reported that 78% of the IFI infected U.S. soldiers injured in Afghanistan from 2009 to
2010 required lower limb amputations.5 However, these fungal infections are problematic
for civilians as well as for the military; for example, invasive Candida infections are the
third most common cause of hospital acquired infections.6
In addition to the presence of multidrug resistant bacteria or fungi, the presence of
necrotic tissue, debris, and fixation devices or implants creates a favorable environment
for the development of biofilms and corresponding infection.7 According to an estimate
by the CDC, approximately 65% of bacterial infections are associated with biofilms.8 In
biofilms, the metabolic activity of the bacteria is reduced, resulting in less susceptibility
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to antimicrobials and an increased minimal inhibitory concentration (MIC). 9
Additionally, the typical clinical presence of multiple bacterial and/ or fungal strains
means that the traditional view of individual pathogen infections and single antimicrobial
delivery may not be appropriate.10
Because systemic antimicrobials cannot be administered at very high
concentrations to fight localized bacteria, fungi, and/or biofilms, local antibiotic delivery
can be an effective route for treating wounds and minimizing infections, when used as an
adjunctive therapy to systemic dosing. 11 Additionally, local delivery systems often have
the capability for the release of multiple antimicrobials for polymicrobial infection
prevention. While there are a large amount of local antibiotic delivery systems available,
there have not many local antifungal delivery systems developed because of the
problematic hydrophobicity of many antifungals. Amphotericin B, a common clinically
used antifungal, has been studied in polymethylmethacrylate (PMMA) bone cement 12-14,
dextran gels15,16, a Pluronic® based gel17, and a composite of hydroxyapatite and
chitosan18,19; however, all of these delivery systems were pre-loaded with the antifungal
and the resulting data varies widely. A local antifungal delivery system capable of
expeditious point of care loading in the operating room would allow a clinician to tailor
the antibiotic and/or antifungal choice and dosage for the needs of each patient.
In previous studies, we developed a degradable chitosan sponge local antibiotic
delivery system that is capable of tailored point of care antibiotic loading and release. 20,21
Additionally, these sponges can be loaded with multiple antibiotics and have released
antibiotics at levels high enough to prevent S. aureus biofilm growth in vivo.20,21 The
water soluble polymer polyethylene glycol (PEG) has also been utilized as a solvent for
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cis-2-decenoic acid, a hydrophobic fatty acid, for incorporation into the same chitosan
sponge delivery system.22 Polyethylene glycol exhibits low toxicity and immunogenicity
and has been used in liposome or nanoparticle form as a solvent system for the systemic
delivery of amphotericin B.23-27 Researchers have also modified chitosan hydrogels,
fibers, and films with PEG, as well as blending or copolymerization. 23,28-30
Therefore, our research purpose was to determine if blending chitosan with PEG
in sponge form would generate a local delivery system capable of releasing both
antibiotic and antifungal for polymicrobial wound infection prevention. The first
objective of this study was to evaluate the sponges’ swelling and in vitro amphotericin B
and vancomycin release, both single and dual loaded, confirm antifungal and antibiotic
activity, and determine the cytocompatibility of the eluates. The second objective of this
research was to evaluate the capability of the chitosan/PEG blended sponges to prevent S.
aureus biofilm growth in vivo in a preliminary infected catheter murine model.
Methods
Materials: Chitosan and polyethylene glycol (PEG) were purchased from Chitinor AS
(Tromsway, Norway) and Sigma Aldrich (St. Louis, MO), respectively. Sodium
deoxycholate solubilized amphotericin B and vancomycin were obtained from Amresco
(Solon, OH) and Fisher Scientific (Pittsburg, PA), respectively. All other reagents and
chemicals were of analytical grade and were purchased from Fisher Scientific.
Sponge Fabrication: To fabricate blended chitosan and PEG sponges, 0.5% (w/v) of
PEG, at 6,000 or 8,000 g/mol, was dissolved in a 1% (v/v) acetic acid solution. After
rapid PEG dissolution, 0.5% (w/v) of chitosan (250 kDa and 82.46 ± 1.679 degree of
deacetylation) was added to the same solution. Control chitosan sponges were made in
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the same manner, but with 1% (w/v) chitosan in solution. Chitosan/PEG and chitosan
solutions were mixed for approximately one hour and then poured into 42 mL aluminum
pans at a volume of 25 mL. Solutions were frozen for a minimum of one hour at -80°C,
followed by lyophilization in a LabConco (Kansas City, MO) FreeZone 2.5 Liter
Benchtop Freeze Dry System.
After lyophilization, the control chitosan sponges and the chitosan/PEG sponges
with 6,000 g/mol PEG were neutralized in either 0.6 or 0.25 M NaOH, respectively.
Sponges were soaked in the base solutions for approximately 1-2 minutes and then
washed in copious amounts of water until a neutral pH was reached. Once neutralized,
the chitosan and chitosan/PEG 6000 sponges were frozen and lyophilized again. The
chitosan/PEG sponges with 8,000 g/mol PEG were only lyophilized once and not
neutralized. All sponge groups were sterilized with low dose gamma irradiation at a
dosage of 25-40 kGy.
Swelling: Sponges were evaluated for their swelling ability by loading the pre-weighed
sponges with 10 mL of 1 x phosphate buffered saline (PBS) via absorbance. After 2
minutes, the sponges were quickly blotted to remove excess surface water and then
weighed immediately (n = 3). The swelling ability of the sponges was calculated using
equation 1,

Swelling Ratio

w
d

where Ww is the wet sponge weight and Wd is the original dry sponge weight.

80

(1)

In Vitro Antifungal and Antibiotic Elution: The in vitro local release of antifungals
and/or antibiotics from the sponges was evaluated by loading the sponges with either 1
mg/ml sodium deoxycholate solubilized amphotericin B, 4 mg/ml vancomycin, or a
combined solution of 4 mg/ml and 1 mg/ml solution of vancomycin and sodium
deoxycholate solubilized amphotericin B. All antimicrobial solutions were created in
sterile Ultrapure water, and the dual vancomycin and amphotericin B solution was made
by creating separate antibiotic and antifungal solutions first and then combining the two
solutions into one. All antimicrobial solutions were shaken immediately prior to use and
10 mL of each solution was added to the sponges (n = 3). After approximately one
minute of absorbance, the antimicrobial solutions not absorbed by the sponges was
removed and measured. Sponges were added to twenty mL of sterile 1x PBS in 125 mL
Nalgene (Rochester, NY) containers and incubated at 37°C on a shaker. Elution samples
were removed after 1, 3, 6, 24, 48, and 72 hours in 1 mL aliquots and the PBS was
completely refreshed.
The concentration of single loaded amphotericin B released from the sponges was
measured via high pressure liquid chromatography (HPLC) with a ThermoScientific BDS
Hypersil C18 column. Amphotericin B was measured at 407 nm in a mobile phase of
acetonitrile, methanol, and 10 mM sodium phosphate monobasic (41:10:49). 31 Both
single and dual loaded vancomycin eluates were also measured with HPLC and the same
column. Vancomycin was measured at 235 nm in a mobile phase of 35% acetonitrile and
65% buffer (0.08 M disodium phosphate and 0.013 M monosodium phosphate adjusted to
pH 3 with phosphoric acid).32
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The concentrations of amphotericin B released from sponges loaded with both
vancomycin and amphotericin B were also measured with ultraviolet visible (UV-Vis)
spectroscopy since the antifungal was not accurately detected using the previously
mentioned HPLC method. According to an amphotericin B manufacturer 33, the typical
detection methods used for amphotericin B detection include microbial assays, HPLC,
and UV-Vis; however, these methods have not been studied with simultaneous
vancomycin elution. Because some of the dual elution samples exhibited precipitates, the
eluates were added 1:1 to dimethylsulfoxide (DMSO) and well mixed. The highly
concentrated stock solution was diluted in DMSO multiple times. Amphotericin B
eluates from dual loaded sponges were read via absorbance at 389 nm in a Biotek
(Winooski, VT) Synergy H1 plate reader. Antifungal concentrations were calculated
using an amphotericin B standard curve.
In Vitro Antifungal Activity: To determine if the amphotericin B released from the
single and dual loaded sponges maintained activity against a common fungi, a microbial
zone of inhibition assay was conducted. The amphotericin B eluates were lyophilized for
one day, reconstituted in 5 μL of PBS, and used to inoculate blank discs. Standard
amphotericin B concentrations, ranging from to 2.5 μg in .25 μg increments, were also
used to inoculate blank discs. A 0.5 McFarland standard of Candida albicans was
prepared in sterile PBS and used to streak a Mueller-Hinton agar plate in three different
directions. An inoculated disc was added to each plate and plates were incubated
overnight at 37°C. The zone of inhibition was measured for each amphotericin B
standard and a standard curve was generated. Zone of inhibition of amphotericin B
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eluate samples were also measured and compared to the standard curve to determine
sample concentration.
In Vitro Antibiotic Activity: To determine if the vancomycin released from the single
and dual loaded sponges maintained activity against bacteria, a bacterial turbidity assay
was conducted following The Clinical and Laboratory Standards Institute standard M7A4, “Methods for Dilution Antimicrobial Susceptibility for Bacteria that Grow
Aerobically”.34 Dilutions (1:10) of vancomycin eluates from single and dual loaded
sponges were tested against S. aureus (UAMS-1). Vancomycin eluate samples were
added in 2

μL increments to .75 mL of sterile trypticase soy broth (TSB) and 5 μL of

S. aureus inoculum with approximately 2x106 colony forming units (CFU). Sterile 1x
PBS was also used as a positive control. The inoculated elution samples were then
mixed, incubated at 37°C overnight, mixed again and read via absorbance at 530 nm in a
spectrophotometer.
In Vitro Cytocompatibility: The in vitro cytocompatibility of the amphotericin B,
vancomycin, and combination amphotericin B and vancomycin elution samples was
tested on normal human dermal fibroblasts (NHDFs) purchased from Lonza
(Walkersville, MD). Cells (passages 9 through 12) were seeded at 2.5 x 10 4 cells/ml in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with

fetal bovine

serum (FBS), penicillin (100 units/mL), streptomycin (100 mg/mL), and amphotericin B
( .25 μg/ml) on 48 well polystyrene tissue culture plates (TCP) under standard cell
culture conditions (37°C and 5% CO2). Elution samples were pre-warmed and diluted
1:1 in fresh medium (n = 3), absent of additional antibiotics and antimycotics. After cells
reached near confluence, the cell culture medium was aspirated from the plates and
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refreshed with the medium and eluate dilution samples. Cells were incubated for one or
three days before cytocompatibility was evaluated with the Cell Titer-Glo®
Lumincescent Cell Viability assay, obtained from Promega (Madison, WI). A standard
dilution of known concentration of cells was also plated and assayed. The luminescent
signal, which corresponded to the amount of adenosine triphosphate and the number of
viable cells based on the standard curve, was recorded at 590 nm with a BioTek Synergy
H1 plate reader. The number of viable cells was converted to cell viability percentage by
normalization to the TCP controls in each respective plate.
In Vivo Mouse Study: In vivo prevention of S. aureus biofilm growth by vancomycin
loaded chitosan/PEG sponges was assessed in 20 NIH Swiss mice, following an
established mouse model protocol.35,36 This in vivo study was approved by the
institutional review board at the University of Arkansas for Medical Sciences (IACUC
protocol #3461). Mice were anesthestized with isoflurane in an environmental chamber
and anesthesia was confirmed by lack of toe pinch reflex. The mice were shaved and a
0.3 cm incision was made in the skin on each flank. A 1 cm section of
polytetrafluoroethylene (PTFE) catheter was placed under the skin on each flank. At the
same time, the chitosan/PEG 6000, chitosan/PEG 8000, or control chitosan sponges were
loaded with either 4 mg/ml vancomycin or 1x PBS solutions (4 animals and 8 catheters
per group) and were placed adjacent to the catheters. Incisions were closed with surgical
glue and 1 cc of 104 CFUs of S. aureus (UAMS-1 strain) was injected into the lumen of
the catheter. After 48 hours post-surgery, mice were sacrificed and catheters were
surgically removed from each flank and placed in a sterile saline solution. The catheters
were sonicated in PBS to remove adherent bacteria; the resulting bacteria aliquots were
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then plated on tryptic soy agar and incubated at 37°C overnight in order to count the
number of CFUs of S. aureus recovered from each catheter.
Statistical Analysis
All data, except for the percent clearance of bacteria from the mouse model, is
presented as mean ± standard deviation. One way ANOVA was used to analyze the
swelling ratios of the sponges. Antifungal and antibiotic elution and antifungal activity
was analyzed using three way Analysis of Variance (ANOVA) with Holm Sidak post hoc
analysis. Eluate cytocompatibility data was analyzed with three way ANOVA with Holm
Sidak post hoc analysis compared to the controls. Colony forming unit data from the in
vivo mouse model was analyzed with the nonparametric Kruskal-Wallis one way
ANOVA on ranks with Tukey post hoc analysis. Statistical significance level was set at
α

. 5.

Results
Results from the swelling analysis of the blended chitosan/PEG and control
chitosan sponges are provided in Table 1, along with critical details about each sponge
formulation. As expected, the blended sponge with 1 lyophilization exhibited a
significantly higher average swelling ratio than the chitosan sponge. The chitosan/PEG
6000 sponge with 2 lyophilizations also exhibited a higher swelling ratio than the
chitosan sponge.
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Table 1. Formulation variables and swelling ratios (n = 3) of blended chitosan/PEG and
chitosan sponges, where * indicates p = 0.033 versus each other.
Sponge
PEG MW
Number of
NaOH
Swelling Ratio
(g/mol)
lyophilizations concentration
Chitosan/PEG 6000 6000
2
0.25 M
19.82 ± 5.72
Chitosan/PEG 8000 8000
1
N/A
23.21 ± 0.91*
Chitosan
N/A
2
0.6 M
12.94 ± 1.63*

The in vitro amphotericin B (the sodium deoxycholate form) release profiles of
chitosan/PEG and chitosan sponges, loaded with amphotericin B alone or in combination
with vancomycin, are shown in Figure 1. All sponges released amphotericin B, alone and
in combination with the antibiotic, well above the amphotericin B minimum inhibitory
concentration of Candida albicans over the 72 hour elution. The dual loaded sponges also
released more amphotericin B than the single loaded sponges, especially after one hour of
elution. Overall significant differences could be seen in the antifungal release between
the chitosan/PEG 6000 single and dual loaded sponges (p = 0.003).
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Figure 1. Sodium deoxycholate solubilized amphotericin B released in vitro in µg/ml
(mean ± standard deviation) from single loaded and dual loaded (with vancomycin)
sponges over time (n 3), where * indicates p < . 5 pairwise overall, and † represents p
< 0.05 pairwise at the respective time point.

Unlike the antifungal elution, vancomycin release from single and dual loaded
blended and chitosan sponges (Figure 2) decreased quickly after the initial burst release.
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Figure 2. (A) Vancomycin released in vitro in µg/ml (mean ± standard deviation) from
single loaded and dual loaded (with amphotericin B) sponges over time (n = 3), where at
each respective time point, * indicates p < 0.001 versus other loading condition within
sponge group, † represents p < . 5 versus all other sponges, and ** denotes p < 0.001
versus all sponge types in loading condition, and (B) an inset graph of (A).
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All sponges released vancomycin at levels above the S. aureus MIC through 24
hours, but only the dual loaded chitosan/PEG 8000 and chitosan sponges released
vancomycin above the MIC through 72 hours of elution. The chitosan/PEG 8000 single
loaded sponge also released significantly more vancomycin than the other dual loaded
sponges after one hour of elution and than all other sponges after three hours.
Additionally, the opposite behavior to the amphotericin B release appeared in the
sponges’ vancomycin release; instead of the dual loaded sponges releasing more
antibiotic, the single loaded sponges release more vancomycin than the dual loaded.
Antifungal activity zone of inhibition assay results, reported as amphotericin B
concentration in μg/ml, are shown in Figure 3. All selected amphotericin B eluates
remained active against C. albicans at all time points. After three hours of elution, the
same trend was found as in the antifungal elution data, where the dual loaded sponges
released more active amphotericin B than the single loaded sponges. However, the
chitosan/PEG 6000 dual loaded sponge did not exhibit higher average levels of active
antifungal than the same single loaded sponge after one hour of elution (p = 0.616).
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Figure 3. Results from antifungal activity zone of inhibition assay using selected
amphotericin B eluted from chitosan/PEG and chitosan sponges, where * indicates p =
.
and † represents p
. 2 pairwise.

The activity of vancomycin released from single and dual loaded chitosan/PEG
and chitosan sponges against Staphylococcus aureus is reported in Table 2. All sponges
released vancomycin active against the bacteria over six hours of elution, and the dual
loaded chitosan sponges still inhibited bacterial growth through 24 hours. As previously
reported in Figure 2, the dual loaded chitosan sponges released more amphotericin B at
24 hours of elution than the other sponge groups.
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Table 2. Activity of 1:10 dilutions of vancomycin released (both single loaded and
dual loaded with amphotericin B) from blended chitosan/PEG and control chitosan
sponges against S. aureus
Hours of Elution
Loading Sponge
1
3
6
24
48
72
Single
Chitosan/PEG 6000 2 lyo
+
+
+
Single
Chitosan/PEG 8000 1 lyo
+
+
+
Single
1% Chitosan
+
+
+
Dual
Chitosan/PEG 6000 2 lyo
+
+
+
Dual
Chitosan/PEG 8000 1 lyo
+
+
+
Dual
1% Chitosan
+
+
- and + indicate no bacterial growth or the growth of bacteria, respectively (n = 3)

As seen in Figures 4A-C, the one hour amphotericin B elution samples from
single loaded chitosan/PEG sponges caused significant decreases in cytocompatibility
from the control tissue culture plastic plate after one and three days of treatment.
However, these same sponge eluate samples exhibited a rebound effect on the viability
after one hour or three hours of elution for chitosan/PEG 6000 and 8000 sponges,
respectively. An increase in cell viability occurred from one to three days of treatment
for most time points, except for the one and 72 hour time points for all sponges.
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Figure 4. Cytocompatibility (mean ± standard deviation) of single loaded amphotericin B
eluates (n = 3) from the (A) chitosan/PEG 6000 sponge, (B) chitosan/PEG 8000 sponge,
and (C) control chitosan sponge, to normal human dermal fibroblasts after one and three
days. Cells was analyzed using Cell Titer-Glo® luminescent assay and resulting cell
numbers were converted to percent cell viability by normalization to tissue culture plastic
(TCP) controls. (* indicates p<0.05 versus TCP controls)

As expected, vancomycin eluted from single loaded chitosan/PEG and chitosan
sponges exhibited higher cell viability than the released amphotericin B (Figures 5A-C).
However, while none of the elution samples exhibited significantly lower cell viability
than the TCP controls after one day of treatment, all elution samples for each sponge
group exhibited lower cell viability than the controls after three days of treatment.
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Figure 5. Cytocompatibility (mean ± standard deviation) of single loaded vancomycin
eluates (n = 3) from the (A) chitosan/PEG 6000 sponge, (B) chitosan/PEG 8000 sponge,
and (C) control chitosan sponge, to normal human dermal fibroblasts after one and three
days. Cells was analyzed using Cell Titer-Glo® luminescent assay and resulting cell
numbers were converted to percent cell viability by normalization to tissue culture plastic
(TCP) controls. (* indicates p<0.05 versus TCP controls)

Combination vancomycin and amphotericin B eluted from all dual loaded sponge
types caused high decreases in cell viability after one day of treatment (Figures 6A-C),
but no statistical difference was found over time for the elution time points (p = 0.279).
However, these same eluates exhibited higher cell viability after three days of treatment
from six to 72 hours of elution from their respective one treatment day numbers. The one
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and three hour elution samples from the chitosan/PEG 6000, 8000, and chitosan sponges
exhibited significantly lower cell viability than the controls, and the 72 hour elution
sample from chitosan/PEG 8000 sponge also cause a significant decrease in cell viability
(p < 0.001).

Figure 6. Cytocompatibility (mean ± standard deviation) of dual loaded vancomycin and
amphotericin B eluates (n = 3) from the (A) chitosan/PEG 6000 sponge, (B)
chitosan/PEG 8000 sponge, and (C) control chitosan sponge, to normal human dermal
fibroblasts after one and three days. Cells was analyzed using Cell Titer-Glo®
luminescent assay and resulting cell numbers were converted to percent cell viability by
normalization to tissue culture plastic (TCP) controls. (* indicates p<0.05 versus TCP
controls)
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Results from the in vivo S. aureus biofilm prevention mouse model are provided
in Figures 7A and B. As seen in Figure 7A, the vancomycin loaded chitosan/PEG 6000
sponge resulted in 100% bacteria clearance from the catheters. Six of the eight catheters
used with the vancomycin loaded chitosan/PEG 8000 sponges were cleared, while only
50% of the catheters treated with the vancomycin loaded chitosan sponges were cleared.
Additionally, as revealed by Figure 7B, the average colony forming units on the
colonized catheters from the vancomycin loaded chitosan/PEG 8000 and chitosan sponge
treatments were significantly lower than the CFUs from the PBS loaded chitosan/PEG
8000 sponge treatment (p = 0.038 and p = 0.032).
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Figure 8. (A) Percentage of catheters cleared of S. aureus and (B) the average colony
forming units (CFUs) per catheter for catheters retrieved from mice treated with
chitosan/PEG 6000, chitosan/PEG 8000, and chitosan sponges (four animals and eight
catheters). Sponges were loaded with either PBS or 4 mg/ml of vancomycin (Vanc) *
indicates p < 0.05 versus PBS loaded sponges.
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Discussion
Polymicrobial musculoskeletal infections, especially from invasive bacteria ,
fungi or biofilm pathogens, are challenging complications that often increase patient
morbidity, mortality, and hospitalization costs. 37 The clinical need for degradable local
antimicrobial delivery systems to fight localized bacteria, fungi, and/or biofilms with
patient tailored antimicrobial point of care loading has resulted in the previous
development of a chitosan sponge local delivery system. 11,20,21 Our research was
designed to determine if the blending of these chitosan sponges with polyethylene glycol
would result in local drug delivery systems capable of antifungal and antibiotic release
for the prevention of polymicrobial wound infections.
After previous sponge formulation and material characterization, the selected
chitosan/PEG sponges were evaluated for their swelling, in vitro amphotericin B and
vancomycin release, both alone and in combination, as well as activity and
cytocompatibility of the resulting antimicrobial eluates. 38 The chitosan/PEG 6000
sponge formulations exhibited higher in vitro amphotericin B release when loaded with
vancomycin, while the chitosan/PEG 8000 sponge exhibited the highest swelling and
released more vancomycin in vitro, both alone and in combination with the antifungal.
Antibiotic eluates from the blended sponges did not exhibit differences in activity against
S. aureus and all the amphotericin B elution samples tested remained active against C.
albicans. Antifungal eluates from blended sponges, both alone and in combination with
vancomycin, caused significant decreases in cell viability after one and three hours of
elution, compared to controls. However, cells recovered as the time of amphotericin B
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elution increased, when the amphotericin B concentrations were reduced in the samples.
Interestingly, vancomycin elution from the blended chitosan sponges exhibited opposite
behavior in vivo to in vitro vancomycin release. In the mice, the vancomycin loaded
chitosan/PEG 6000 sponge cleared 25% and 50% more of the bacteria from the catheters
than the vancomycin loaded chitosan/PEG 8000 and chitosan sponge, respectively.
Comparing the blended chitosan/PEG sponges to the sparse previous literature on
local antifungal delivery, there are some similarities and differences to published research
on local antifungal delivery systems. 12,13,17,39 While the blended sponges in this study still
retainined amphotericin B, both the chitosan/PEG 6000 and 8000 sponges released more
antifungal in vitro in comparison to previously reports for amphotericin B loaded PMMA
bone cement. Kweon et al.13 and Goss et al.12 have reported bone cement to release 0.45
and 0.05%, with and without a poragen, or 0.03% of loaded amphotericin B, respectively.
However, the chitosan/PEG sponges released less antifungal than the 60% cumulative
amphotericin B released after two days from a preloaded Pluronic® based copolymer
gel.17 Additionally, the amphotericin B eluates from the sponges in this study are similar
to the reported active amphotericin B eluted from PMMA bone cement. 39 While
antifungal released from the blended sponges reduced cell viability after one hour of
elution, previous research has confirmed amphotericin B’s negative effects on cells, when
exposed to high concentrations.40 Harmsen and researchers have studied amphotericin B
at typical locally delivered concentrations and found amphotericin B at
fibroblast death after 5 hours, while 5 and

μg/ml caused

μg/ml caused abnormal cell morphology

and reduced proliferation after 7 days and 5 hours and 7 days, respectively.40
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The in vitro local vancomycin release from the blended sponges can also be
compared to previous studies on antibiotic loaded chitosan sponges. 20,21,41 Vancomycin
release after one hour of elution, from single or dual loaded sponges, was 23-52% and
12-59% higher from the chitosan/PEG sponges than previously studied vancomycin
loaded crosslinked chitosan sponges.41 However, unlike the blended sponges, these
previously studied crosslinked sponges released vancomycin at levels above the S. aureus
MIC throughout the entire 72 hours of elution. 41 The chitosan/PEG 8000 sponge, loaded
with vancomycin only, initially released more vancomycin in vitro than previously
reported for chitosan sponges made with lactic and acetic acid and loaded with 5 mg/ml
vancomycin; however, the blended sponge did not release high enough levels of
vancomycin throughout the entire elution study to inhibit S. aureus growth as long as
described in the previous study.20
Limitations of this study include the challenging in vitro measurement of
amphotericin B concentration when released simultaneously with vancomycin and the
lack of direct comparison in the antifungal and antibiotic activity assays due to the
different dilutions utilized in the studies. However, this study is one of the few published
studies on the simultaneous in vitro loading and release of amphotericin B and a
representative antibiotic, vancomycin. Additionally, the small number of animals and
antibiotic concentrations studied in the pilot in vivo study should be increased in future
animal studies. However, the initial results of the preliminary in vivo model provide a
sufficient trend of the in vivo behavior of the blended chitosan sponges to prevent biofilm
formation. Although additional work is needed to evaluate in vivo release of amphotericin
B, the blended chitosan and polyethylene glycol sponges may provide a way to locally

99

deliver clinician selected antifungals and/or antibiotics for use as an adjunctive therapy
for the prevention of polymicrobial musculoskeletal wound infections.
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CHAPTER 5
CONCLUSIONS
The results presented in this dissertation indicate that the chitosan sponge can be
modified, either through buffering with sodium acetate or blending with polyethylene
glycol (PEG), to create local drug delivery systems with different in vitro material
properties and in vivo functionality for wound infection prevention. Chapter 2
demonstrated the capability to modify the properties of the chitosan sponge through a
buffering procedure to increase degradation and still remain biocompatible. Additionally,
the results indicate that one can adapt the characteristics of the sponge based on the
intended application, for example, a short or long length of degradation.
The polyethylene glycol and chitosan blended sponges developed in Chapters 3
and 4 also confirmed chitosan’s modification potential, but through blending with an
additional polymer instead of a buffer. By adding PEG to the chitosan sponges, an
increase in in vitro water insoluble amphotericin B release was seen, as well as increased
activity of the antifungal eluates compared to the control unmodified chitosan sponges.
Similar to the buffered sponges from Chapter 2, the chitosan/PEG sponges also exhibited
increased in vitro degradation from the original chitosan sponges and remained
cytocompatible (Chapter 3). Specifically, the chitosan/PEG 8000 1 lyo sponge
demonstrated increased in vitro degradation from both buffered sponges, and the
chitosan/PEG 6000 1 lyo sponge exhibited increased degradation from the pH 5.6
buffered sponge. Modifying the chitosan sponge with PEG also resulted in similar cell
viability results to the buffered chitosan sponges. In the in vivo intramuscular rat model,
the chitosan/PEG blended sponges revealed higher percentage of implant area in the
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defect area than the buffered sponges. However, the PEG modified sponges exhibited
less fibrous tissue overall and a decreased average graded inflammatory response after
ten days of implantation than the buffered chitosan sponges. Both the buffered and PEG
modified chitosan sponges exhibited reduced in vivo degradation compared to their in
vitro degradation analyses.
Chapter 4 described an in vitro and in vivo evaluation of the functionality of the
chitosan/PEG sponges for local antifungal and antibiotic release and infection prevention.
The chitosan/PEG sponges with a PEG molecular weight of 6,000 g/mol and two
lyophilizations exhibited a slight increase in in vitro water soluble amphotericin B release
(single loaded) after one hour of elution, but the chitosan/PEG 8000 sponge with one
lyophilization demonstrated increased in vitro vancomycin elution from either single or
dual loaded sponges, compared to the other sponge groups. However, the opposite
behavior was seen in the pilot in vivo Staphylococcus aureus biofilm infection prevention
mouse model, where the vancomycin loaded chitosan/PEG 6000 and 8000 sponges
cleared 100% and 75% of the bacteria from the implanted catheters, respectively. Both
antibiotic loaded PEG modified sponges exhibited improvements in biofilm prevention
over the control unmodified chitosan sponges, loaded with vancomycin or PBS. These in
vitro and in vivo results indicate the potential use of the antifungal and/or antibiotic
loaded chitosan/PEG sponge local delivery system for use as an adjunctive therapy to
prevent bacterial and fungal wound infections. However, as recommended in Chapter 6,
additional research is needed to confirm in vivo chitosan/PEG sponge functionality for
prevention of fungal infections.
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In conclusion, these results provide strong support of the stated hypothesis: that
modified chitosan sponges, with a buffer or polyethylene glycol, will function as
degradable local antimicrobial delivery systems for use as an adjunctive therapy to
prevent infection establishment in musculoskeletal wounds. The PEG modified chitosan
sponges were specifically shown to function as a local delivery system for both
hydrophilic antibiotics and hydrophobic antifungals, loaded alone or in combination.
While additional work is needed to confirm the in vivo degradation of both types of
modified sponges, the significant in vitro degradation indicates the potential for eventual
degradation. With additional research, both of these modified chitosan sponges could
meet the clinical need of reliable, low-cost polymicrobial infection prevention that can be
used as an adjunctive topical therapy to surgical debridement and irrigation and systemic
antibiotic regimens.

106

CHAPTER 6
RECOMMENDATIONS FOR FUTURE WORK
Additional research evaluations should be conducted on the chitosan/PEG sponge
in order to develop a more thorough understanding of the sponge’s properties and its
functionality for local antifungal delivery and infection prevention. More in vitro elution
studies and activity research with other antifungals, such as voriconazole, or other
hydrophobic compounds could extend the possible applications of the modified chitosan
sponge. The chitosan/PEG sponges should also be evaluated for in vitro antibiotic
delivery with antibiotics other than vancomycin and tested against bacteria other than
Staphylococcus aureus.
In order to increase degradation, PEG with a lower molecular weight could be
blended with chitosan because previous research has shown a link between molecular
weight and degradation.44,59 Additionally, an extended in vivo degradation study for both
the PEG modified and buffered chitosan sponges would provide a more accurate length
of time for complete degradation. In order to assess the in vivo functionality of the
modified sponges for fungal infection prevention, it is also recommended that
amphotericin B loaded chitosan/PEG sponges be evaluated in an in vivo fungal infection
model. Finally, both the buffered and chitosan/PEG sponges should be studied in an in
vivo large animal model, with traumatic musculoskeletal wounds more applicable to
clinical cases.
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APPENDIX A
PRELIMINARY FORMULATION RESEARCH
Prior to the resulting chitosan and polyethylene glycol sponge formulations
described in Chapters 3 and 4 of this dissertation, extensive formulation research was
performed in order to reach the final sponge formulations. The variables tested and
selected for the final sponge formulations, along with the reasons for selection are
reported in Table 1.

Table 1. Chitosan and polyethylene glycol sponge formulation variables tested
Variable
Variable Tested
Reason for Selection
Weight percentage
1% or 2%
Degradation
Chitosan: PEG Ratio
1:1, 2:1, or 4:1
Elution & degradation
Chitosan Supplier
Primex or Chinitor AS
Supplier change
DDA
61%, 71%, or 82%
Supplier change
PEG MW (g/mol)
6,000, 8,000, or 10,000
Degradation
NaOH concentration (M)
0.25, 0.6, or 1
Degradation & swelling
Acid type
1% Lactic/acetic acid (75:25) Degradation & sponge
or 1% acetic acid
flexibility
Freezing temperature
-20°C or -80°C
Freezer space, no
difference otherwise
Order of addition
Chitosan first or PEG first
Easier to dissolve
chitosan
Number of lyophilizations
1 or 2
Degradation
Bold indicates the variable was selected for the final chitosan/PEG sponge formulations.

In the first round of sponge formulations, 1:1, 2:1, and 4:1 Chitosan: PEG sponges
were prepared in 1% acetic acid. Chitosan with a DDA of 71% from Primex and PEG
with a molecular weight of 8,000 g/mol were used for each sponge type. All of the
sponges were lyophilized twice and neutralized in 1 M NaOH. The in vitro lysozyme
based degradation of the sponges was analyzed, as well as the in vitro water insoluble
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amphotericin B elution; both experiments were previously described in Chapter 3. The
percentage of sponge remaining after two or four days of in vitro degradation is shown in
Figure 1. None of the chitosan/PEG blended sponges exhibited any significant
differences in sponge degradation over time.

Figure 1. Mean in vitro lysozyme mediated degradation of first chitosan/PEG sponge
formulations over time.

The elution profile of water insoluble amphotericin B from the 1:1, 2:1, and 4:1
chitosan/PEG sponges is provided in Figure 2. Once again, not many significant
differences can be seen between the sponge groups, except that the 2:1 chitosan/PEG
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sponge released slightly more amphotericin B after one and three hours than the other
formulations. Because not many differences in degradation or antifungal elution were
revealed between the three original sponge formulations, the 1:1 chitosan/PEG sponge
was selected due to the belief that this sponge formulation would exhibit increased
degradation after changing the sodium hydroxide concentration.

Figure 2. Mean amphotericin B (water insoluble) elution (±standard deviation) from first
round of chitosan/PEG sponge formulations over 72 hours.

In the second round of formulation research, 1:1 chitosan/PEG sponges were
developed in 1% acetic or blended (75:25 lactic: acetic) acid. Chitosan with 61% or 71%
DDA and PEG with a molecular weight of 6,000 or 8,000 g/mol were utilized to make
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the sponges. One sponge was made by dissolving chitosan in the acid first, followed by
PEG. The remaining sponges were fabricated by dissolving PEG first. Sponges were
neutralized in 0.25, 0.6, or 1 M NaOH, frozen at -80°C, and lyophilized twice. The
swelling ability of the sponges in water was characterized, following the procedure
described in Chapter 4 (Figure 3). The chitosan/PEG sponge neutralized in 0.25 M
NaOH exhibited the highest swelling ratio compared to the other sponges. These results
led to the decision to select 0.25 M NaOH for neutralizing the modified chitosan sponges.

Figure 3. Swelling of second round of chitosan/PEG sponge formulations in water
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In the third round of formulation research, 1:1 chitosan/PEG sponges were fabricated
in 1% acetic or blended (75:25 lactic: acetic) acid. Sponges were prepared with either
61% or 71% DDA chitosan and 6,000, 8,000, or 10,000 g/mol PEG. All sponges were
neutralized in 0.25 M NaOH and lyophilized twice. Another in vitro degradation study
was conducted with these chitosan/PEG sponge formulations, and these results are
provided in Figure 4.

Figure 4. In vitro degradation of second round of chitosan/PEG sponge formulations after
4 days in 1 mg/ml lysozyme solution, all sponges were made with 1% blended acid
unless otherwise noted.
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As shown in the degradation results, the sponge formulated with 1% acetic acid
exhibited significant increased degradation than the sponges formulated with 1% blended
acid. Thus, acetic acid was selected as the sponge solvent for future chitosan/PEG
sponge formulation.
After the third round of sponge formulations, our laboratory changed chitosan
suppliers from Primex to Chitinor AS. Whereas Primex produced 61% and 71% DDA
chitosan, Chitinor AS produced chitosan with an average 82% DDA. This specific
chitosan was selected because our industrial research partner, Bionova Medical, used this
chitosan to manufacture chitosan sponges.
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APPENDIX B
ADDITIONAL CYTOCOMPATIBILITY EVALUATIONS
Objective
In vitro cytocompatibility of materials is a useful tool to screen potential
candidates for eventual in vivo implantation. Cell viability results from a direct contact
study with the chitosan/PEG sponges and the antimicrobial sponge eluates are reported in
Chapters 3 and 4, respectively. However, additional microscopic evaluation and live/dead
staining of the normal human dermal fibroblasts (NHDFs) in direct contact with the
chitosan/PEG sponges was conducted in order to identify cellular morphology.
Additionally, cytocompatibility of cells in contact with standard solutions of
amphotericin B and vancomycin, both alone and in combination, was assessed to identify
cytotoxic concentrations of the antimicrobials, independent of the antimicrobial elution
from the sponges. The stock antibiotic and antifungal solutions used to load the
chitosan/PEG sponges in Chapter 3 were also tested for cytocompatibility.
Live/Dead Staining
Normal human dermal fibroblasts were seeded in 12 well tissue culture plastic
plates at 2.89 x 104 cells/ml in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and penicillin (100 units/mL),
streptomycin (100 mg/mL), and amphotericin B (0.25 µg/mL) under standard cell culture
conditions (37°C and 5% CO2 atmosphere). Cells were allowed to proliferate to near
confluence, after which cell culture medium was aspirated and refreshed with 1 mL of
fresh medium. Chitosan, chitosan/PEG, and control polyurethane sponges were soaked in
pre-warmed, sterile 1 x PBS for approximately 20 minutes. A single 8 mm diameter test
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specimen (n = 5) was then gently placed in a well in direct contact with the cell
monolayer. Cultures were incubated for one day before biocompatibility and cellular
morphology was assessed with the LIVE/DEAD® Viability/Cytotoxicity kit, obtained
from Molecular Probes. Cell culture media was removed and replaced with Live/Dead
solution, which consisted of 35 μl of 2 mM ethidium homodimer-1 and 25 μL of 4 mM
calcein in 1 x PBS. Plates were incubated at room temperature before images of the
stained cells were taken with an EVOS microscope at 4 x magnification. Representative
images of stained cells after one day of direct contact with the sponges are shown in
Figure 1.

Figure 1. Images of normal human dermal fibroblasts stained with calcein (live cells)
and ethidium homodimer-1 (dead cells) after one day of direct contact with the 1%
chitosan sponge, chit/PEG 6000 1 lyo, chit/PEG 6000 2 lyo, chit/PEG 8000 1 lyo,
chit/PEG 8000 2 lyo, and a control polyurethane sponge (at 4 x magnification)
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All of the sponges exhibited good cell viability, with hardly any visible dead cells
present. However, there are a few differences in cellular morphology. While the
chitosan/PEG 6000 1 lyo, chitosan/PEG 6000 2 lyo, and chitosan/PEG 8000 1 lyo
sponges all exhibited similar effects on cell morphology as the polyurethane sponges, the
1% chitosan and chitosan/PEG 8000 2 lyo sponges caused slight cellular malformation.
The cells exposed to these two sponge groups exhibited reduced elongation. This effect
on in vitro cellular morphology led to the decision to exclude the chitosan/PEG 8000 2
lyo sponge from future experimental analysis.
Antimicrobial Solution Cytocompatibility
To evaluate the effects of both stock and standard solutions of amphotericin B and
vancomycin, both alone and in combination, normal human dermal fibroblasts were
seeded at 2.5 x 104 cells/ml in 48 well plates in the same cell culture conditions described
in Chapter 4. Standard concentrations of amphotericin B and vancomycin at 1000, 100,
10, and 1 μg/ml and 4000, 400, 40, and 4 μg/ml, respectively,were prepared in 1:1
dilutions in sterile pre-warmed media. Standard concentrations of vancomycin and
amphotericin B in combination were also prepared at a total antimicrobial concentration
of 5000, 500, 50, and 5 μg/ml (4000, 400, 40, and 4 μg/ml and 1000, 100, 10, and 1
μg/ml of vancomycin and amphotericin B combined). The original stock loading
solutions of amphotericin B and vancomycin, both alone and in combination, from
Chapter 4 were also diluted in media, along with a PBS control.
After cells reached near confluence, culture media was removed and replaced
with the antimicrobial solution dilutions. Cells were incubated for one or three days,
after which cell viability was assessed with the Cell Titer-Glo® Luminescent Cell
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Viability assay, purchased from Promega. The luminescent signal, which corresponded
to the amount of adenosine triphosphate and the number of viable cells through a
standard dilution of known concentrations of cells, was recorded at 590 nm using a
BioTek Synergy H1 plate reader. Cell concentrations were converted to percentage of
cell viability by comparison to tissue culture plastic controls, which were represented as
100% cell viability.
Results from the cytocompatibility study with standard antimicrobial solutions are
provided in Figure 2, while the cytocompatibility data from stock antimicrobial solutions
used to load chitosan and chitosan/PEG sponges is shown in Figure 3. As expected, a
large difference in cell viability exists between the vancomycin and amphotericin B
solutions, both in the standards and stock solutions. Amphotericin B is known to be toxic
at high levels; one previous study has found that concentrations of 100 μg/ml caused cell
death after five hours.60 However, the modified sponges studied in this work did not
release amphotericin B at levels high enough to cause severe cell death, as seen in the
1000 and 100 μg/ml samples in Figure 2. Not surprisingly, the dual vancomycin and
amphotericin B solutions also exhibited similar cytotoxicity to amphotericin B alone; the
dual solutions contained the same amount of amphotericin B as the single solutions.
Interestingly, the vancomycin solutions exhibited larger decreases in cell viability from
one to three days of treatment than the amphotericin B and dual antimicrobial solutions.
However, the PBS group also exhibited this decreased cell viability, which indicates this
effect might be simply due to the dilution of media over three days.
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Figure 2. Cytocompatibility (mean ± standard deviation) of (A) standard vancomycin
solutions (n = 3), (B) standard amphotericin B solutions (n = 3), and (C) standard
vancomycin and amphotericin B combination solutions to normal human dermal
fibroblasts after one and three days. Cells were analyzed using Cell Titer-Glo®
luminescent assay and resulting cell numbers were converted to percent cell viability by
normalization to tissue culture plastic (TCP) controls. (* indicates p<0.05 versus all, **
indicates p<0.05 versus all except ‡, and † denotes p<0.05 pairwise)
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Figure 3. Cytocompatibility (mean ± standard deviation) of normal human dermal
fibroblasts after one and three days of treatment of stock amphotericin B, vancomycin,
and combination vancomycin and amphotericin B solutions (n = 3) used to load
chitosan/PEG and chitosan sponges in in vitro antimicrobial elutions. (* indicates p<0.05
versus all within respective timepoint)
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APPENDIX C
EVALUATION OF TWO SOURCES OF CALCIUM SULFATE FOR A LOCAL
DRUG DELIVERY SYSTEM: A PILOT STUDY
Introduction
Wound infection and osteomyelitis can be challenging to treat especially with
complex musculoskeletal trauma in civilian and military populations, and can result in
multiple surgeries and increased costs [1,2]. Local drug delivery is emerging as a useful
route for treating acute and chronic wound infections. Because drugs are delivered to the
entire body in systemic drug delivery, toxicity issues can often arise as well as antibiotic
resistance [3]. Organisms that are typically antibiotic-resistant in systemic delivery can be
more susceptible to the higher levels of antibiotics provided through local delivery [3].
Additionally, the drug can take a longer time to reach the wound when delivered
systemically and some avascular areas of the body are unreachable [3]. In local drug
delivery, the wound area is targeted and the drug does not substantially affect other parts
of the body; however, local drug delivery systems do not completely eliminate toxicity
issues and antibiotic resistance. The ideal local drug delivery system would be
implanted, deliver antibiotics at appropriate levels and lengths of time based on
application, and then degrade so there would be no need for a second surgical procedure
for removal [3].
Another difficult challenge with complex musculoskeletal trauma is resistant
bacteria. Wound infection can be complicated by wound contamination with antibioticresistant bacteria, which can increase treatment difficulty. Methicillin-resistant
Staphylococcus aureus (MRSA) is a serious concern in modern medicine and serves as a
problem in wound treatment. Antibiotic-resistant bacteria have created a need for newer
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antibiotics as an adjunct for past antibiotic selections such as vancomycin. Daptomycin is
a semisynthetic antibiotic with activity against Gram-positive bacteria and has
demonstrated activity against MRSA [4,5]. Daptomycin has been previously researched
combined with a calcium sulfate (CaSO4) carrier, and daptomycin reportedly elutes
similarly to tobramycin in vitro [6,7]. However, like with many antibiotics used for
infected wound treatment, bacterial resistance to daptomycin has been recently reported
[8].
CaSO4 has been previously used as a bone void filler and in bone defects is
absorbed by the surrounding tissue, possibly accelerating bone healing [9]. CaSO4 is a
biocompatible, biodegradable material with osteoconductive properties that exhibits a
bolus, or burst, release followed by an extended drug release from several hours to weeks
depending on the formulation [10,11]. CaSO4 has been used to deliver vancomycin,
gentamycin, tobramycin, lincomycin, cefazolin, teicoplanin, and fucidin [12-14].
Another, and the most common, material used for local drug delivery is
polymethylmethacrylate (PMMA) [15]. Although PMMA implants are not
biodegradable, their removal may be necessary at times for planned staged reconstruction
or late bead failure [16]. Because CaSO4 degrades over time, the need for surgical
removal is eliminated. Clinical studies and animal models suggest using antibiotic-loaded
calcium sulfate pellets minimizes infection [17-19]. Although there are numerous
potential applications in which calcium sulfate is beneficial as a drug delivery material,
the mechanical properties of calcium sulfate do make it insufficient for load-bearing
applications [20]. Recently, two sources of CaSO4 that are commercially available have
been studied for their use in local antibiotic delivery. To make pellets with daptomycin
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from one type of CaSO4 (hemihydrate synthesized from naturally occurring USP grade
gypsum), a catalyst, K2SO4, is required [7]. It has been proposed the K2SO4 catalyst
would not be necessary to form pellets from a synthetic CaSO4. A comparison of
antibiotic elution, pellet degradation, and the need for a catalyst of these two CaSO 4
sources has not been investigated.
We asked the following questions: (1a), is the pellet degradation and (1b),
daptomycin elution profile different for two different forms of CaSO4, naturally sourced
from gypsum and synthetic; (2) does the presence of a catalyst, potassium sulfate
(K2SO4), affect the degradation and the daptomycin elution profile of the CaSO 4 pellets
manufactured from two different sources; and (3) is the daptomycin released from both
sources of CaSO4 pellets active against bacteria associated with osteomyelitis,
specifically S. aureus?
Materials and Methods
To determine whether the pellet degradation, daptomycin elution profile, and
activity against S. aureus were affected by the type of CaSO4 or the presence of a
catalyst, we prepared the CaSO4 pellets in three groups, synthetic CaSO4 and 3% K2SO4,
synthetic CaSO4 and 0% K2SO4, and naturally sourced CaSO4 with 3% K2SO4 as seen in
Figure 1. Four of each type of pellet was placed in each vial and there were four total
replications, or vials, for each group in each test. Each pellet group was tested in an
elution study, degradation study, and activity testing with the dependent variables being
daptomycin concentration, degradation rate, and turbidity, respectively.
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Synthetic CaSO4
pellets with 0%
K2SO4

Synthetic CaSO4
pellets with 3%
K2SO4

Sourced CaSO4
pellets with 3%
K2SO4

Degradation tests performed with three
CaSO4 pellet groups loaded both with
and without 5 wt% daptomycin (n= 4
with 4 pellets per replication). Weights of
pellets were measured and percentage of
original pellet remaining calculated.

Elution tests performed with three CaSO4
pellet groups, loaded with 5 wt%
daptomycin (n= 4 with 4 pellets per
replication). Concentrations were
measured by high pressure liquid
chromatography.

Turbidity assays performed on eluates
obtained from elution study (n= 4 with 4
pellets per replication). Eluates
containing daptomycin were evaluated
for inhibitory antibiotic levels against S.
aureus.

Figure 1. A flowchart demonstrates the study design with the three test groups and the
key variables from three property characterization tests.
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The two types of CaSO4 used in our study were Osteoset (Wright Medical
Technology, Arlington, TN), a sterile surgical grade, CaSO4 α-hemihydrate from
naturally sourced United States Pharmacopeia (USP) grade gypsum, and Stimulan
(Biocomposites, Wilmington, NC), a high-purity, completely synthetic sterile CaSO4αhemihydrate. The naturally sourced and synthetic CaSO4 pellets were both cast with 4.75
g of CaSO4, with and without 5 wt%, 0.25 g, of daptomycin (Cubist Pharmaceuticals Inc,
Lexington, MA; Lot MCB2007). The 5 wt% was previously determined using prior
research on naturally sourced CaSO4 pellets [6,7]. Throughout our study, we used aseptic
techniques in the fabrication of the pellets. The synthetic CaSO 4 pellets were made with
and without 2.5 mL of sterilized 3% K2SO4 solution, whereas the naturally sourced
CaSO4 pellets were only made with 2.5 mL of 3% K2SO4 solution. Previous research has
determined that a concentration of 3% K2SO4 is necessary for the naturally sourced
CaSO4 pellets because the pellets will not retain their shape without the catalyst [6]. The
3% K2SO4 solution was substituted with 1.7 mL of sterile phosphate-buffered saline for
the synthetic CaSO4 pellets with 0% K2SO4. We carried out all experiments in four
replications (n = 4). Pellets were cast using 3-mm OSTEOSET® Resorbable Mini-Bead
Kits (Wright Medical Technology; Catalog 8400-0511; Lot LB04-0028-27) and
following the mixing method used by Wright Medical Technology described in previous
research [6,7].
We performed the elution statically with four sets of each pellet variation
distributed into four steam autoclaved 20-mL glass scintillation vials. The elution was
conducted without stirring to maintain the structure of the pellets. We loaded 4 mL of
phosphate-buffered saline (PBS) into each vial and placed them in an oven at 37° C. The
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eluates were mixed and 1-mL samples were taken at Days 1, 2, 4, 6, 8, and 10. The
elution studies were stopped at 10 days because the antibiotic levels were below the
HPLC detection limit. After each day’s eluate sample was collected, we replaced the
remaining liquid with a fresh 4 mL PBS and the vials were returned to the 37° C oven.
Eluate samples were immediately frozen in a Fisher Scientific Isotemp freezer at -20° C.
To measure the initial daptomycin concentration loaded in the pellets, samples
were made of each pellet variation were constructed and crushed before placing them into
a PBS solution. The drug content of the pellets was measured before the elution because
previous CaSO4 and daptomycin pellets had some daptomycin loss from initial loading.
The percent daptomycin content loaded into the pellets was compared with the percent
daptomycin released from the elution.
To determine the eluate’s antibiotic concentration, we performed high-pressure
liquid chromatography (HPLC) testing according to previously used methods [7]. The
Varian (Palo Alto, CA) HPLC system was comprised of a ProStar 240 Solvent Delivery,
ProStar 410 Autosampler, and ProStar 325 UV-Vis Detector modules. We performed
module control and data processing using Varian’s Gala ie Chromatography Data
System (Version 1.8.508.1). The mobile phase consisted of a HPLC-grade acetonitrile
and water (62:38, v/v) solution including 4 mM ammonium dihydrogen phosphate
brought to a pH of 3.25 using glacial acetic acid. Separation was accomplished using a
Varian Microsorb-MV C8 column, 150-mm length and 4.6-mm inner diameter, with a
flow rate of 1 mL/min. Daptomycin was detected at 232 nm with a retention time of 13.8
minutes. We performed the method in a temperature range of 23.3 ± 1.1° C.
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We determined the CaSO4 pellets’ degradation by a common weight-based
experiment 1-3. Initially, the weights of clean 20-mL glass scintillation vials were
established and then the weight of each vial with four pellets of an individual variation
was measured. We loaded 4 mL of PBS into each vial and stored them at 37° C. At 1-, 2-,
4-, 6-, 8-, and 10-day time points, the PBS was removed and the pellets were allowed to
dry at 7 ° C until a constant vial and pellet weight was obtained. After each time point’s
sample was collected, we placed 4 mL PBS into the vials and they were returned to 37° C
storage. The degradation was determined by the percent of pellets remaining at each time
point calculated using the following relationship:
Percent remaining (%) = (vial and pellets at × hours weight – vial weight)(mg)/(vial and
initial pellets weight - vial weight)(mg) × 100
We determined antibiotic activity against S. aureus (Cowan I strain obtained from
Dr David Hasty, University of Tennessee Health Science Center) by using antibiotic
elution samples in a turbidity assay. In this experiment, solution clarity after sufficient
bacterial incubation with antibiotic eluates indicated bacterial inhibition resulting from
antibiotic activity. As instructed by the protocol provided by the manufacturer, we
supplemented BBL™ Mueller Hinton II Broth (Becton, Dickinson and Co, Sparks, MD;
Lot 0071612) with 25 µg/mL Ca2+ in order to achieve a total Ca2+ concentration of 50
µg/mL. Two hundred microliters of daptomycin eluates were added to the inoculum
containing 1.75 mL Mueller Hinton II Broth + Ca2+ and 50 µL S. aureus in 5-mL
polystyrene test tubes. The experimental setup created a 1:10 dilution of all eluates.
Experimental groups, blanks containing neither S. aureus nor eluate samples, and positive
controls containing S. aureus without antibiotic eluates were mixed and incubated at 37°
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C. After approximately 20 hours of incubation at 37° C, we vortexed the tubes and the
absorbance at 530 nm was recorded.
All data are presented as mean ± SD and met the assumptions of a parametic test.
We determined differences in percent degradation and daptomycin concentration between
the pellets made from two different types of CaSO 4 and the pellets made with and
without K2SO4 using repeated measures analysis of variance and Tukey’s post hoc
analysis using 2007 Microsoft Office Excel (Microsoft Inc, Redmond, WA) and 2004
SigmaStat (San Jose, CA). Differences in degradation were also analyzed with KaplanMeier survival analysis with log rank, where 10% of the original pellet remaining was
classified as failure of the pellets. When only 10% of the original pellet remains, the
antibiotic concentration in the pellets is typically too low and the pellets are too small to
accurately measure.
Results
The degradation studies indicated differences between the sourced and synthetic
CaSO4 pellets with 3% K2SO4 without daptomycin at Days 2 (p = 0.002), 4, 6, and 8
(p < 0.001), as seen in Figure 2. However, Kaplan Meier analysis with log rank revealed
no overall differences between all three CaSO4 groups without daptomycin (p = 0.368).
When 5 wt% daptomycin was incorporated into the pellets (Figure 3), differences were
seen between the sourced CaSO4 pellets and the synthetic CaSO4 with 0% K2SO4 at Days
1 through 10 (p < 0.001).
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Figure 2. The graph shows the degradation results of the naturally sourced and synthetic
CaSO4 pellets with 0% daptomycin present. There were differences in average
degradation of naturally sourced and synthetic CaSO4 pellets with 3% K2SO4 and
naturally sourced and synthetic CaSO4 pellets with 0% K2SO4 at Days 2, 4, 6, and 8.
Differences were observed between the synthetic CaSO4 pellets with 3% and 0% K2SO4
at Days 4, 6, and 8. Degradation is reported in wt% of original pellet remaining ± SD
with n = 4 (*corresponds to p < 0.001).

133

90

Sourced CaSO4 pellets, 3% K2SO4, 5% daptomycin

*
*

80

*

% of Original Pellet Remaining

70

*

Synthesized CaSO4 pellets, 3% K2SO4, 5% daptomycin
Synthesized CaSO4 pellets, 0% K2SO4, 5% daptomycin
*

60

*

*

*

*

*

*

*

50
40
30
20
10
0
1

2

4

6

8

10

Time (days)
Figure 3. The graph shows the degradation results of the naturally sourced and synthetic
CaSO4 pellets with 5% daptomycin present. We observed differences in average
degradation of naturally sourced and synthetic CaSO4 pellets with 0% K2SO4 and
synthetic CaSO4 pellets with 3% and 0% K2SO4 at Days 1-10. Degradation is given in
wt% of original pellet remaining ± SD with n = 4 (*corresponds to p < 0.001).

Using Kaplan Meier analysis with log rank, overall differences were seen between
the sourced and synthetic CaSO4 pellets with 0% K2SO4 (p < 0.001) and between the
synthetic CaSO4 pellets with 3% and 0% K2SO4 (p <0.001). However, no differences
were seen between the degradation of the sourced and the synthetic CaSO4 pellets with
3% K2SO4 (p > 0.05) from the ANOVA or Kaplan Meier survival analysis.
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We observed differences in the elution profile of the sourced CaSO4 pellets and
the synthetic CaSO4 pellets with 3% K2SO4 at Day 1 (p < 0.001) and Day 2 (p = 0.002)
(Figure 4). The sourced CaSO4 pellets released the highest amount of daptomycin on Day
1 and correspondingly had the highest amount of cumulative daptomycin eluted (Figure
5), but the synthetic CaSO4 pellets with 3% K2SO4 released the largest amount of
antibiotic on Day 2.
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Figure 4. The graph shows the elution results from the naturally sourced and synthetic
CaSO4 pellets with 5% daptomycin loaded, with mass and concentration of daptomycin
released on the primary and secondary y axes, respectively. We found differences in the
average mass and concentration of daptomycin released in the eluates between the
naturally sourced and synthetic CaSO4 pellets with 3% and 0% K2SO4 at Days 1 and 2.
Differences are shown in average mass and concentration of daptomycin released in the
eluates between the synthetic CaSO4 pellets with 3% and 0% K2SO4 at Day 2. Mass and
concentration are given in micrograms and micrograms per milliliter, respectively, of
daptomycin released per pellet ± SD with n = 4 (*corresponds to p < 0.001).
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Figure 5. The graph shows the elution results in the cumulative release form from the
naturally sourced and synthetic CaSO4 pellets, with and without 3% K2SO4, with 5%
daptomycin loaded. Mass is given in micrograms of daptomycin released per pellet ±
SD with n = 4.

For evaluation of mass balance in these studies, the average percent daptomycin
loaded and released from the three types of pellets was measured. The average percent of
daptomycin for the sourced CaSO4 pellets was highest at loading, at 85.1%, but the
percent daptomycin released was highest in the synthetic CaSO4 pellets with 3% K2SO4
at 48.8% (Table 1). The average percent daptomycin was lowest, both loaded and
released, in the synthetic CaSO4 pellets with 0% K2SO4.
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Table 1. Average percent daptomycin loaded in pellets and released in elution testing
Pellet Type

% Daptomycin Loaded

% Daptomycin Released

Sourced CaSO4 Pellets with
3% K2SO4

85.1

42.8

Synthesized CaSO4 Pellets
with 3% K2SO4

81.8

48.8

Synthesized CaSO4 Pellets
with 0% K2SO4
Values are mean (n = 4)

45.8

39.3

The presence or absence of K2SO4 created differences in the degradation and the
elution in the synthetic CaSO4 pellets. The synthetic CaSO4 pellets with 0% K2SO4 and 5
wt% daptomycin degraded much more quickly than both types of pellets with 3% K2SO4,
and as previously mentioned, differences were seen in degradation between the synthetic
CaSO4 pellets with 0% K2SO4 and the other pellets using ANOVA and Kaplan Meier
analysis. Differences were seen in the elution (Fig 4) between the synthetic CaSO 4 pellets
with 0% K2SO4 and 3% K2SO4 at Day 2 (p < 0.001) and the naturally sourced CaSO4
pellets with 3% K2SO4 at Day 1 (p < 0.001) and Day 2 (p = 0.002).
The eluates of the sourced CaSO4 pellets with 3% K2SO4 and 5 wt% daptomycin
demonstrated sufficient activity against S. aureus with no bacterial growth at Days 1, 4,
and 6 (Table 2). Eluates from synthesized CaSO4 pellets with 0% K2SO4 were only active
against S. aureus at Days 1 and 2; however, the eluates from the synthesized CaSO4
pellets with 3% K2SO4 were active against S. aureus at all time points except at 10 days.
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Table 2. The average activity for 5% loaded daptomycin (1:10 dilution)
against of Staphylococcus aureus
Time points (days)
Pellet Type
1 2 4 6 8 10
Sourced CaSO4 Pellets with 3% K2SO4
+ + +
Synthesized CaSO4 Pellets with 3% K2SO4
+
Synthesized CaSO4 Pellets with 0% K2SO4
+ + + +
( - ) indicates inhibition of S. aureus, ( + ) indiciates growth of S. aureus, (n = 4)

Discussion
The treatment of osteomyelitis is becoming complicated by the increased
emergence of antibiotic-resistant bacteria and increases the need for local drug delivery
over systemic delivery. The purpose of our study was to evaluate parameters of a local
CaSO4 drug delivery system, including (1a) to determine if the pellet degradation and
(1b) daptomycin elution profile is different for two different commercially available
forms of CaSO4; (2) to examine if the presence of a catalyst, K2SO4, affects the
degradation and antibiotic elution profile of the CaSO4 pellets; and (3) to verify the
daptomycin released from both types of CaSO4 pellets is active against S. aureus, a
bacterium commonly associated with osteomyelitis.
Our study is limited by several factors. First, a common limitation of most in
vitro research is the difficulty of translating in vitro studies to in vivo studies [16].
Release characteristics in an in vivo environment, especially associated with a wound, are
different than antibiotic release characteristics in vitro, in which a set volume of eluate
and PBS is exchanged at certain intervals [16]. This study is not meant to serve as a
surgical wound model itself, but as a supplement to in vivo studies. Additionally,
although we are testing four pellets at one time, elution, degradation, and activity
properties of these pellets may be completely different in vivo in larger pellet quantities.
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Second, we tested activity of the antibiotic to planktonic S. aureus and did not test
inhibitory activity to bacteria within biofilms, which can be more resistant to antibiotic
therapy and typically require additional antibiotic levels required for inhibition of
planktonic bacteria [23]. Third, we used only one antibiotic. Increasing the number of
evaluated antibiotics could predict if the CaSO4 type or presence of K2SO4 impacts drug
elution and pellet degradation in different ways. Fourth, both elution and degradation are
dependent on numerous factors, including physical and chemical properties of materials,
elution volumes with and without fluid exchange, and antibiotic interactions and thus we
cannot predict elution and degradation performance across all potential applications.
Both elution and degradation studies only provide details about the release and
degradation characteristics of the local delivery vehicle itself, and do not account for
affects from a local wound and the interactions between the delivery system, fluid, and
drug.
Our preliminary data indicate differences in degradation and elution between both
forms of CaSO4 pellets, naturally sourced and synthetic, that could affect the clinical
selection of a local delivery system. As with previously researched sourced CaSO4
pellets, all pellets exhibited a bolus release of antibiotics on Day 1 [21,26]. However,
the total percent release of daptomycin from the naturally sourced CaSO4 pellets was
higher and the concentration of daptomycin released on Day 1 was lower than previously
reported (Table 3) [6,7]. The initial daptomycin released from the naturally sourced and
synthetic calcium sulfate pellets is closer to initial antibiotics eluted from PMMA beads
(Table 3) [24-26]. An explanation for the higher total release of the antibiotic could be
the result of faster elution to measurement activities in comparison to previous studies.
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Extended elution and storage could impact stability of daptomycin in solution. The lower
initial daptomycin concentration could be explained by the larger size of the previously
researched CaSO4 pellets [21,26]. Although the synthetic CaSO4 pellets also exhibited a
bolus release, more daptomycin was eluted on Day 2 compared with the naturally sourced
CaSO4 pellets, which could demonstrate a slower antibiotic release.
The difference in daptomycin release could be partially explained by the
degradation differences between the types of pellets. The synthetic CaSO 4 pellets with
3% K2SO4 and 5% daptomycin demonstrated the slowest degradation, as compared to the
other two types of pellets. Although the naturally sourced CaSO4 pellets had a faster
degradation than the synthetic CaSO4 pellets with 3% K2SO4, the degradation of the
naturally sourced CaSO4 pellets in our study was slower than previously reported [7].
However, the results could have been different because distilled water was used for the
degradation solution instead of PBS in the previous research [7]. The presence of
daptomycin increased the degradation rate in all three pellet types studied, but had the
greatest effect on the degradation of the synthetic CaSO4 pellets with 0% K2SO4. An
explanation for this difference in degradation that has been previously reported could be
that when the K2SO4 is absent, the daptomycin prevents the setting reaction of the CaSO4,
which impacts the stability of pellets [21].

141

Table 3. Comparisons of present study with previous research on CaSO 4 and PMMA
Study
Type of
Antibiotic
Catalyst/ Drug
Degradation Activity
material
additive release on
testing
Day 1
Richelsoph Sourced Daptomycin K2SO4
537.3
Yes
No
et al. [21]
CaSO4
or
µg/mL/g
100%
tobramycin
daptomycin degraded at
and 827.6
6 days
µg/mL/g
tobramycin
Webb et
Sourced Daptomycin K2SO4
697.4
N/A
Yes:
al. [26]
CaSO4
µg/mL/g
inhibition
for clinical
through
pellets
28 days,
except
Days 10
& 14
Kanellako- Synthetic Daptomycin None
1320.1
N/A
No
poulou et
CaSO4
µg/mL
al. [11]
McLaren
PMMA
Daptomycin None,
84.375
N/A
No
et al. [18]
xylitol
µg/mL
or
with xylitol
glycine
-3
Lewis and PMMA
Gentamicin None
≈
N/A
N/A
Janna [13]
sulfate
g/mL/h for
4.25 wt%
loading
Lewis et
PMMA
Daptomycin None
< 50
N/A
Yes:
al. [12]
µg/mL/g
inhibition
for 4.5
through 7
wt%
days
loading
Parker et
Sourced Daptomycin K2SO4
97.48
Yes
Yes:
al. (current CaSO4
µg/mL
21% of
inhibition
study)
original
at Days
pellets
1, 4, and
remaining
6
at 10 days
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Table 3 continued. Comparisons of present study with previous research on CaSO 4 and
PMMA
Study
Type of
Antibiotic
Catalyst/ Drug
Degradation Activity
material
additive release
testing
on
Day 1
Parker et al
Synthetic Daptomycin K2SO4
76.16 Yes
Yes:
(current study)
CaSO4
µg/mL 30.9% &
inhibition
with
2.25% of
at Days 1
3%
original
and 2
K2SO4 pellets with with 0%
and
3% & 0%
K2SO4
74.19 K2SO4
and Days
µg/mL remaining
1-8 with
with
at 10 days
3%
0%
K2SO4
K2SO4
PMMA = polymethylmethacrylate; N/A = not applicable

Although it has been previously determined that K2SO4 is necessary to form
pellets of naturally sourced CaSO4 [7], we were able to form pellets out of synthetic
CaSO4 without the K2SO4 catalyst. By not incorporating K2SO4 into the pellets, the
synthetic CaSO4 pellets degraded much more rapidly and released less daptomycin than
the other pellets with the catalyst present. The daptomycin released from the synthetic
CaSO4 pellets with 0% K2SO4 is substantially less than the amount released from the
same type of CaSO4with 0% K2SO4 that was previously reported (Table 3) [27].
However, the local delivery pellets used in these previous research studies were much
larger than the pellets in this current research, 160 by 100-mm compared with 3-mm
pellets, and Mueller Hinton broth was used as the elution vehicle instead of PBS [27].
Our preliminary data suggest the eluted daptomycin from both naturally sourced
and synthetic CaSO4 pellets, with and without K2SO4, is active against S. aureus,
inhibiting bacterial growth for varying lengths of time. While the synthetic CaSO4 pellets
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with 3% K2SO4 demonstrated the highest activity against S. aureus, the synthetic pellets
with 0% K2SO4 provided inhibition of S. aureus on Days 1 and 2 only, which can be
explained by the low amount of daptomycin eluted from the pellets compared to the
pellets with K2SO4. The inhibitory activity of the synthetic pellets with 0% K2SO4 is
much lower than previously reported daptomycin inhibition of S. aureus from CaSO4 and
PMMA; however, the bacterial inhibition of the synthetic CaSO4 pellets with 3% K2SO4
is much higher than the same reported data [12,26]. The positive growth measured on
Day 2 for the naturally sourced CaSO4 pellets may have been caused by an unknown
contaminant because there were similar amounts of daptomycin present in the pellets on
Days 4 and 6. Additionally, similar naturally sourced CaSO4 pellets were previously
reported to inhibit S. aureus for 10 days without any contamination and inhibited S.
aureus for 28 days with two cases of contamination [6].
This preliminary research provides researchers and clinicians with additional
information on the two commercially available forms of CaSO4 for a local delivery
system for infection prevention or treatment. Our study has also shown although K2SO4 is
not necessary for forming pellets from synthetic CaSO4, it may be helpful for decreased
degradation, an increased daptomycin elution profile, and potentially extended activity
against susceptible organisms. Further investigations, including preclinical in vivo studies
and biofilm associated investigations, are needed to determine functional differences and
applications of these local drug delivery systems.
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APPENDIX D
A DAPTOMYCIN-XYLITOL-LOADED POLYMETHYLMETHACRYLATE
BONE CEMENT HOW MUCH XYLITOL SHOULD BE USED?
Introduction
A recurring challenge with total joint arthroplasty (TJA) is periprosthetic joint
infection (PJI) [13, 39, 49]. The prevalence of this phenomenon is variable, ranging from
0.3% to 9% for primary cases [11, 48] and from 2% to 40% for revision cases [24, 49].
The ramifications are serious for the patient (in most cases, revision is necessary using,
for example, the two-stage method [38]) and treatment costs are high (for example, in
2009, in the United States, the mean total charge for revision of an infected THA was
approximately USD 94,000 [21]). Thus, there have been many efforts to reduce the
likelihood of PJI [13, 24] and improve treatment options [38, 45].
One approach to improving treatment is to use an antibiotic-loaded
polymethylmethacrylate (PMMA) bone cement (ALABC) in which the cement powder is
blended with a novel antibiotic [15, 31]. Novel antibiotics are considered those with
potential to have rapid and effective bactericidal activity against pathogens, such as
methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis, that have
become resistant to many of the common antibiotics used in current approved
commercially available ALABC brands or orthopaedic surgeon-prepared/directed
formulations (such as gentamicin, tobramycin, and vancomycin [13, 39, 45]). Although
there is a growing number of these novel antibiotics (eg, dalbavancin, daptomycin,
telavancin, and tigecycline) [4, 8, 10, 12, 15, 19, 31, 42, 45], only a few, such as
daptomycin and telavancin, have been used in PJI treatment [15, 31].
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Several studies have reported the in vitro properties of either low-dose
daptomycin-loaded PMMA bone cement (low-dose is defined as  1 g daptomycin per 40
g cement powder [13]) [5, 14, 26] or a higher-dose variant ( 2 g) [5, 14, 26, 41]. These
reports show the daptomycin release profile in phosphate-buffered saline (PBS) solution,
at 37° C, is characterized by a burst followed by a period of slow decrease [5, 14, 26]. At
relatively low amounts (up to 7.5% of the mass of the dry cement powder-daptomycin
mixture), the daptomycin e erts a marginal influence on the cement’s fatigue limit,
tensile strength, yield strength, compressive strength, and compressive modulus
(compared to the value for a cement that did not contain the antibiotic) [14, 26, 41], but
with a higher amount of daptomycin (11 wt/wt%), there is an appreciable drop in the
cement’s fatigue limit [26]. There is a sizeable literature on methods to improve the
release profile of antibiotics from ALABC cylinders, including incorporation of a
particulate filler (such as lactose, mesoporous silica nanoparticles, or xylitol) in the
cement powder [9, 37, 43] and subjection of cured cement specimens to continuous or
intermittent watt-level low-frequency ultrasound [3]. However, none of these reported
methods have been evaluated for daptomycin-loaded PMMA bone cement. Also, in the
case of an ALABC loaded with a poragen, the question as to the appropriate poragen
amount has not been fully investigated.
We therefore asked: What is an appropriate amount of xylitol to be used in a
daptomycin-xylitol-loaded PMMA bone cement?
Materials and Methods
The study design comprised three parts as seen in Figure 1. (1) We prepared four
groups of cement, one not loaded with the xylitol and three having different xylitol
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masses, namely, 0.7, 1.4, and 2.7 g; (2) For each of these four groups, we determined the
following cement properties: fracture toughness, fatigue limit, daptomycin release rate,
coefficient of diffusion for outflow of daptomycin (Ddapt), an index of activity of the
daptomycin eluate against S aureus, polymerization rate at 37° C, coefficient of diffusion
for intake of 1X PBS solution, and radiopacity (see Figure 1 for numbers of specimens or
replicates used for each type of testing). These determined properties are of clinical
relevance [17, 25, 29, 35, 41, 43, 44]. (3) We used an optimization method to assess an
appropriate xylitol amount.
The materials used were a commercially available brand of PMMA bone cement
(Orthoset® 1; Wright Medical Technology, Inc, Arlington, TN, USA), daptomycin
(Cubicin®; Cubist Pharmaceuticals, Lexington, MA, USA), and xylitol (XyloSweet ®;
XLEAR, Orem, UT, USA). The daptomycin amount used (1.36 g/40 g dry cement
powder) was determined, from our previous work [26], based on the fatigue life, rate of
release of daptomycin, and activity of the released daptomycin against S aureus of
daptomycin-loaded Othoset® 1 cement. The xylitol amounts (X) of the cements in the
four study groups were 0, 1.66, 3.27, and 6.13 wt/wt% of the total dry cement powder
mixture mass. In a separate study, we used a volumetric displacement method in a liquid
in which the powder was not soluble to determine the densities of the dry cement powder,
daptomycin, and xylitol to be 1.25, 1.20, and 1.50 g cm-3, respectively. Thus, the
corresponding xylitol amounts were 0, 1.39, 2.74, and 5.16 vol/vol% of the total dry
cement powder mixture volume.
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Figure 1. A flowchart shows the study design. The key features of the eight cement property characterization tests conducted are
shown: fracture toughness (Y1), fatigue limit (Y2), daptomycin elution rate (Y3), diffusion coefficient for daptomycin egress (Y4),
inhibition index (Y5), polymerization rate, at 37° C (Y6), diffusion coefficient for PBS intake (Y7), and normalized radiopacity (Y8).
Study sets were no xylitol (XYL-00), 0.7 wt/wt% xylitol (XYL-07), 1.4 wt/wt% xylitol (XYL-14), and 2.7 wt/wt% xylitol (XYL-27).
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Before the preparation of the cement groups, the daptomycin was stored at 4° ± 1°
C, while the xylitol and the cement powder and liquid monomer were stored in ambient
laboratory conditions (temperature and relative humidity of 21° ± 1° C and 57% ± 2%,
respectively). A commercially available cement powder mixer (OmoMix ®; Tecres SpA,
Verona, Italy) was used to mix the dry cement powder, daptomycin, and xylitol.
For the fracture toughness tests, the final powder mixture and the liquid monomer of the
cement (18.37 mL) were vacuum-mixed using a commercially available unit (MixeVac®
II High-Vacuum System; Stryker Instruments, Kalamazoo, MI, USA), with an evacuation
pressure of 74 ± 1 kPa. The prepared cement dough was injected into a stainless steel
mold whose internal configuration and dimensions were of a compact tension test
specimen, whose dimensions conformed to those stipulated in ASTM D5045 [2]: overall
nominal height, width, and thickness = 35.7 mm, 37.2 mm, 14. 9 mm, respectively. The
protocols used for finishing the specimens, accepting specimens for testing, conditioning
the accepted specimens, performing the tests, and treating the results to obtain the
fracture toughness (KIC) of the cement were the same as those given in our previous work
[30].
For the fatigue tests, the prepared cement dough was injected into a four-celled
silicone mold, with each cell having internal configuration and dimensions of a solid
cylindrical dog bone, whose dimensions conformed to those stipulated in ASTM F211803 [1]: overall nominal diameter and length = 8.5 mm and 62 mm, respectively.
Protocols for inspecting the fabricated specimens, selecting acceptable specimens,
choosing the specimens to be tested from the acceptable ones, conditioning the test
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specimens, and performing the tests were the same as those given in our previous work
[26]. Per ASTM F2118-03, acceptable specimens are those with no surface defects in the
gage or transition sections and no internal defects with major diameter of larger than 1
mm in the gage section. The acceptable specimens were conditioned in 1X PBS, at 37° ±
1° C, for 7 days before the tests. During the tests, the specimen was immersed in 1X PBS,
at 37° ± 1° C. For each cement group, the combination of applied stress (S) and number
of specimens used were ± 20 MPa (seven specimens), ± 15 MPa (seven specimens), ±
12.5 MPa (five specimens), and ± 10 MPa (three specimens). These stresses have been
used in many literature studies [7, 22, 26, 47], with ± 10 MPa being of the order
postulated to be experienced in the cement mantle in a cemented TJA [18]. The test
results were presented in the form of S versus number of cycles to fracture, Nf (as before
[26], run-out was defined as no fracture after 1.557 million loading cycles). The method
used for estimating the fatigue limit of the cement was the same as that used in our
previous work [26].
For each cement group, 75% to 89% of the fabricated specimens were found
acceptable for fatigue testing but not all were used. From among those not used, three
were selected at random for the daptomycin release tests. These elution tests were
performed using the protocols in our previous study [26]. The amount of daptomycin
released was measured in 10 mL 1X PBS solution, at 37° ± 1° C, at eight time points (t)
of 1, 2, 5, 7, 10, 14, 21, and 28 days, with complete PBS refreshment at each time point.
The release results were compiled as current amount of daptomycin released (W) versus t
and cumulative amount (M) versus t. A commercially available software package
(MATLAB® R2011b; The MathWorks, Natick, MA, USA) was used to obtain the best-fit
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relationship between W and t. The daptomycin release rate was then computed as the
derivative of this W-versus-t relationship calculated at the value of t midway between the
burst release point and the point at which the W-versus-t curve began to flatten.
The release of daptomycin from a test specimen was approximated using the expression
for release of a drug from a specimen possessing aspects of both a long cylinder and a
thin disc [40]. With the aid of a scientific calculator (TI-89 Titanium; Texas Instruments,
Inc, Dallas, TX, USA), the M-versus-t results and the aforementioned expression were
used to compute Ddapt.
After the daptomycin release tests were completed, eluates at each of the eight
time points were tested for an index of antimicrobial activity against S aureus, as
described previously [26]. Thus, 200 µL of eluates were added to 1.75 mL Mueller
Hinton II broth supplemented with 25 µg CaCl2 per mL followed by the addition of an
inoculum of S aureus (~104 colony-forming units [CFUs]) and an overnight incubation at
37° C. Growth was determined by measuring the optical density (OD) of the solutions, at
530 nm, using an ultraviolet spectrophotometer (GENESYS™ 20; Thermo Scientific,
West Palm Beach, FL, USA). The inhibition index (I) was computed as before [26].
The differential scanning calorimetry work was performed at a heating rate of 15 K
minute-1 (DuPont 910; Instrument Specialists, Inc, Spring Grove, IL, USA). The
protocols used and the steps employed in treating the results to obtain the cement
polymerization rate at 37° C (k′) were as described in our previous work [30].
The PBS intake test involved measuring the mass gain of a circular crosssectioned cement disc specimen cut from the end of an acceptable fatigue test specimen
(nominal diameter and thickness of 8.50 mm and 3.00 mm, respectively) immersed in 15
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mL 1X PBS solution at 37° ± 1° C. Measurement continued until there was no observable
increase in mass gain. Details of all the steps involved in using the mass gain versus time
in PBS results to compute the PBS diffusion coefficient (D PBS) were given in our
previous work [30].
The experimental protocols followed for the determination of the radiopacity (R)
of the cement were the same as presented in our previous work [28]. However, in the
present work, R was calculated as the ratio of the linear attenuation coefficient (μ) for the
cement (slope of the linear regression plot of the logarithm of OD of cement disc versus
cement disc thickness) to μ for Al (slope of the linear regression plot of OD of Al stepwedge versus Al step-wedge thickness) and expressed as equivalent Al% [36]. The
normalized radiopacity (R) was computed as the ratio of R to the mass fraction of the
radiopacifier in the cement powder (9.1 wt/wt% BaSO4 for each cement group).
The optimization method used to assess the appropriate xylitol loading comprised
seven steps: (1) for each of the eight cement properties, obtain the best-fit relationship
between the determined values and X; this relationship is called an “objective function”;
(2) for each of the cement properties, find the highest and lowest value, as given in
previous literature; (3) for each cement property, calculate the its fractional objective
function at a given value of X (within the range 0 - 6.13 wt/wt%) as follows: (value of the
objective function at X – lowest literature value of property) divided by (highest literature
value of property – lowest literature value of property); (4) for a property that should be
as high as possible (for example, fatigue limit), calculate the quantity, (fractional
objective function)2 at the X value . Call this quantity Y1. Alternatively, for each
property that should be as low as possible (for example, k), calculate the quantity [1-
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(fractional objective function)]2 at the X level Call this quantity Y2; (5) repeat steps (3)
and (4) for all the properties and hence calculate the master modified fractional objective
function (MMFOF) as equal to (sum of all the values of Y2)-(sum of all the values of
Y1); (6) repeat steps (3) – (5) at other values of X (within the range 0 – 6.13 wt/wt%); (7)
determine the appropriate value of X as that at which the maximum value of MMFOF,
when plotted against X, occurs. Thus, this appropriate value is the one that gives the best
tradeoff among the cement properties. The calculations in step (1) and those in steps (3) –
(7) were carried with the aid of commercially available software packages (TableCurve
2D v5.01; SYSTAT Software Inc, Chicago, IL (USA) and Microsoft® Excel® Solver;
Microsoft Corp, Redmond, WA, USA), respectively.
Results
The results of the daptomycin release profile, the activity of the released
daptomycin against S aureus, fatigue lives, and the other cement properties are presented
in Figure 2, Table 1, Figure 3, and Table 2, respectively.
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(A)

(B)

Figure 2A–B. Graphs shows the daptomycin release profiles in (A) current amount and
(B) cumulative amount. Study sets were no xylitol (XYL-00), 0.7 wt/wt% xylitol (XYL07), 1.4 wt/wt% xylitol (XYL-14), and 2.7 wt/wt% xylitol (XYL-27). The daptomycin
release profile depended on the xylitol amount.
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Table 1. Summary of values of cement properties
Cement KIC
Fatigue Daptomycin Ddapt
release rate (10-11
(MPam)* limit
†
(MPa)
(µg mL-1 d-1 m2 s1
g-1) *
)*

k
(10-3 s1
)

DPBS
(10-12
m2 s1
)*

R’
(equivalent
Al% MR1 ‡§
)

XYL-00 1.92 ±
0.04
XYL-07 1.89 ±
0.06

2.59 ±
2.10
2.21 ±
1.20

4.49 ±
1.05
4.34 ±
1.60

4.51

9.9 (8.3, 45.2
11.6)
9.8 (8.3,
11.3)

34.6

3.75 ±
0.21
2.53 ±
0.63

3.30

XYL-14 1.96 ±
8.8 (6.2, 50.0
2.72 ± 0.67 ±
3.37 ± 3.41
0.02
11.4)
0.26
0.32
1.33
XYL-27 1.88 ±
9.7 (8.6, 74.3
2.44 ± 0.61 ±
5.92 ± 3.63
0.04
10.8)
0.29
0.22
1.15
*Values are expressed as mean ± SD; † values are expressed as mean, with 95% CIs in
parentheses; ‡ values are expressed as mean only; § MR = mass ratio of the radiopacifier
in the cement powder (9.1 wt/wt% BaSO4); KIC = fracture toughenss; Ddapt = coefficient
of diffusion for outflow of Daptomycin; k’ = cement polymerization rate at 37°C; DPBS =
coefficient of diffusion for intake of 1X phosphate-buffered saline solution; R’ =
normalized radiopacity; XYL-00 = no xylitol; XYL-07 = 0.7 wt/wt% xylitol; XYL-14 =
1.4 wt/wt% xylitol; XYL-27 = 2.7 wt/wt% xylitol.
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Figure 3. A graph summarizes the fatigue test results. At stresses of the order experienced
in the cement mantle in a cemented TJA (10 MPa), xylitol did not adversely affect fatigue
life. Study sets were no xylitol (XYL-00), 0.7 wt/wt% xylitol (XYL-07), 1.4 wt/wt%
xylitol (XYL-14), and 2.7 wt/wt% xylitol (XYL-27). Values are shown as mean with
standard deviation.
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Table 2. Summary of activity test results
Cement Growth/inhibition of Staphylococcus aureus*
Elution time (days)
1
2
5
7
10
14

Mean
inhibition
index†
21
28
(%)
XYL-00 +
+
+
62.5
XYL-07 100
XYL-14 -/+‡
95.8
XYL-27 100
* + = growth of S. aureus (inhibition index = 0); - = inhibition of S. aureus (inhibition
index = 100%); † for a cement, index = (sum of inhibition indexes/total number of test
specimens (= 24); ‡of the three samples tested, two inhibited and one allowed growth of
S. aureus; XYL-00 = no xylitol; XYL-07 = 0.7 wt/wt% xylitol; XYL-14 = 1.4 wt/wt%
xylitol; XYL-27 = 2.7 wt/wt% xylitol.

Using these results, the objective functions (which are given in Table 3), and the
optimization method presented, we determined the appropriate xylitol amount to be 4.45
wt/wt% (equivalent to final dry powder mixture composition of 1.93 g xylitol, 1.36 g
daptomycin, and 40 g cement powder).
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Table 3. Summary of the objective functions (that is, best-fit relationships between each
of the properties determined and the xylitol loading (X))
Cement property
Best-fit relationship
Adjusted R2a
Fracture toughness (Y1)

Y1 = 1.924 – 9.205x 10-5 *

0.089

eX
Fatigue limit (Y2)

Y2 = 9.378 + 0.5603 * e-X

Daptomycin elution rate

Y3 = 0.03583 + 0.000327 * 0.7163

(Y3)

X2.5

Diffusion coefficient for

Y4 = 2.587 x 10-11 – 2.022

daptomycin egress (Y4)

x 10-13 * ln (X)

Inhibition index (Y5)

Y5 = 96.77 * X0.01578

0.9575

Polymerization rate, at 37

Y6 = 0.002656 / (1.0 + (x /

0.7776

o

2.598)2.728)

Diffusion coefficient for

Y7 = 4.036 x 10-12 + 4.053

PBS intake (Y7)

x 10-15 * eX

Normalized radiopacity

Y8 = 1/ (0.292-0.069 * eX)

C (Y6)

0.0799

0.8933

0.2028

0.5824

(Y8)
a

Coefficient of multiple determination, adjusted for the degrees-of-freedom of the
equation.

Discussion
In TJAs, it is common practice to use either a commercially available brand or an
orthopaedic surgeon-prepared/directed formulation of an ALABC as a prophylaxis agent
against PJI [13, 39, 49]. There are many reports of substantial decrease in susceptibility
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of the pathogens involved in PJI (such as methicillin-resistant S aureus) to the antibiotic
incorporated in the cement powder (usually, gentamicin, tobramycin, or vancomycin)
[45]. This decrease in susceptibility provides opportunity to develop novel antibiotics.
Among novel antibiotics, there are reports of the effectiveness of daptomycin and
telavancin against these pathogens [15, 31]. Literature reports on daptomycin-loaded
cement cylinders show the daptomycin release rate is low [5, 14, 26]. When a poragen
was added to the cement powder of an ALABC, antibiotic release rate from cylindrical
specimens increased, but there are limited data on the impact on other cement properties
[37]. The question as to what should be an appropriate poragen amount in an ALABC
that contains a poragen has not been posed. In this study, we determined the appropriate
amount of xylitol to be used in a daptomycin-xylitol-loaded PMMA bone cement.
We recognize several limitations of our study. First, although there are reports
indicating xylitol-containing dental products may be useful in preventing or reducing the
progression of dental caries [32]), the question as to the safety of xylitol as a constituent
of an ALABC is an open one. However, there are reports of the beneficial effects of
dietary xylitol against weakening of bone in aged animal models [33]. Thus, a xylitolloaded ALABC may be viable for use in cemented TJAs. Second, we used one cement
brand, one antibiotic, and one brand of xylitol. Given the large numbers of cement brands
and antibiotics available, the present approach is justified from the perspective of study
time and cost. Third, the conditions under which the daptomycin release tests were
conducted are different in a number of respects, notably fluid dynamics and sink details,
from the in vivo medium in which a TJA is located [6, 23]. However, these experimental
conditions reportedly produce vancomycin elution levels that are highly correlated with
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those obtained from the hip of an animal model [50]. Fourth, we used a generalized
measure of the activity of the released daptomycin against S aureus, rather than a specific
one, such as the number of bacteria on a cement specimen (CFUs/surface area of the
specimen). However, the former method was used in each of the other literature studies
of daptomycin release from ALABC cylinders [5, 14, 26]; thus, we can compare present
trends to those in these reports. We note two caveats regarding the appropriate xylitol
loading we determined: (1) Even though a large and diverse array of cement properties
was determined, there are other important ones that were not. One such property is
resistance of a cement specimen to the formation of biofilm of a given pathogen
implicated in PJI on its surface, a phenomenon that may result in a substantial reduction
of the susceptibility of the pathogens to daptomycin [46]. Other undetermined properties
are working time, which gives insight into the time window between packing the cement
dough in the bone bed and placement of the prosthesis in that bed [20]; residual monomer
content, which provides an indication of the potential for phenomena such as chemical
necrosis of periprosthetic tissues [16]; and fatigue crack propagation rate in PBS, at
37° C, which may be related to the in situ life of a TJA [34]. (2) Weighting factors for the
determined cement properties were not used; for example, considering the clinical
application, in a head-to-head comparison between daptomycin release rate and fatigue
limit, the former may be given a higher weighting factor. An investigation of the
sensitivity of the assessed appropriate xylitol loading to the number of cement properties
determined and the calculation of weighting factors for the cement properties determined
are outside the confines of the present study. None of the above-mentioned limitations
and caveats jeopardizes the assessed appropriate xylitol amount. However, these issues
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should be taken into account if the present appropriate xylitol amount result is to be used
in the clinical setting.
In a related study, Nugent et al. [37] investigated the influence of xylitol amount
on the properties of ALABC cylindrical specimens and found antibiotic release increased
progressively and compressive strength of the cement decreased, with increase in xylitol
amount. However, Nugent et al. [37] used a medium-viscosity cement [20], the antibiotic
tobramycin, and xylitol amounts from1 g to 16 g of xylitol per 40 g of cement powder;
hand-mixed the final powder mixture with the cement liquid monomer; and did not assess
an appropriate xylitol amount. In contrast, we used a high-viscosity cement brand [20],
daptomycin, and xylitol amounts from 0.7 g to 2.7 g of xylitol per 40 g of cement
powder; vacuum-mixed the final powder mixture with the cement liquid monomer; and
assessed an appropriate xylitol amount. Two other relevant studies were by Lewis et al.
[26, 27] on the computation of the appropriate amount of the antibiotic in an ALABC.
Two methodologies were used in one study [27], each involving changes of each of the
properties determined with antibiotic dose. The methodology used in the other study [26]
was the same as that used in the present work, but many more cement properties were
determined in the present study (eight versus three). Thus, there are no literature studies
comparable to the present investigation.
In conclusion, we found an appropriate xylitol amount for a daptomycin-xylitolloaded PMMA bone cement was 4.46 wt/wt% (equivalent to 1.93 g xylitol mixed with
1.36 g daptomycin and 40 g cement powder). We recognize that this assessed amount is
based on an analysis of a limited number of in vitro cement properties, including some
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properties, such as the local minimum inhibitory concentration of the eluted daptomycin,
that require confirmation from in vivo studies.
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APPENDIX E.
Animal Use Protocol Approvals

1. The University of Memphis Institutional Animal Care and Use Committee
Protocol Action Form
Protocol 0720 Approval: Antibiotic-loaded biopolymer sponge for prevention
of polymicrobial wound infection (Rat Model, Chapter 2)
2. Department of the Army, US Army Medical Research and Materiel Command,
Animal Care and Use Review Office Protocol Approval Form
Protocol DM090455.02 Approval: Antibiotic-loaded biopolymer sponge for
prevention of polymicrobial wound infection (Rat Model, Chapter 2)
3. The University of Memphis Institutional Animal Care and Use Committee
Protocol Action Form
Protocol 0728 Approval: Biopolymer sponge and paste for prevention of
polymicrobial wound infection (Rat Model, Chapter 3)
4. The University of Arkansas for Medical Science Institutional Animal Care and
Use Committee Protocol Approval Letter
Protocol 3641 Approval: Antibiotic-loaded chitosan devices for wound
infection prevention (Mouse Model, Chapter 4)
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